

Estimates of protection against SARS-CoV-2 infection and severe COVID-19 in Germany before the 2022/2023 winter season - the IMMUNEBRIDGE project

Berit Lange^{§1,2}, Veronika K Jaeger^{§3}, Manuela Harries¹, Viktoria Rücker⁴, Hendrik Streeck^{5,6}, Sabine Blaschke⁷, Astrid Petersmann^{8,9}, Nicole Toepfner¹⁰, Matthias Nauck^{9,11}, Max J Hassenstein¹, Maren Dreier¹², Isabell Von Holt¹², Axel Budde^{5,6}, Antonia Bartz³, Julia Ortmann¹, Marc-André Kurosinski³, Reinhard Berner^{10*}, Max Borsche^{13*}, Gunnar Brandhorst^{8*} Melanie Brinkmann^{12*}, Kathrin Budde^{9*}, Marek Deckena^{14*}, Geraldine Engels^{15*}, Marc Fenzlaff^{9*}, Christoph Härtel^{15*}, Olga Hovardovska^{1*}, Alexander Katalinic^{16*}, Katja Kehl^{5,6*}, Mirjam Kohls^{4,17,18*}, Stefan Krüger^{19*}, Wolfgang Lieb^{20*}, Kristin M Meyer-Schlinkmann^{14*}, Tobias Pischon^{21,22,23*}, Daniel Rosenkranz^{8*}, Nicole Rübsamen^{3*}, Jan Rupp^{24*}, Christian Schäfer^{9*}, Mario Schattschneider^{9*}, Anne Schlegtenthal^{25*}, Simon Schlinkert^{19*}, Lena Schmidbauer^{4*}, Kai Schulze-Wundling^{5,6*}, Stefan Störk^{26*}, Carsten Tiemann^{14*}, Henry Völzke^{27*}, Theresa Winter^{9*}, Christine Klein¹³, Johannes Liese¹⁵, Folke Brinkmann²⁵, Patrick F Ottensmeyer^{5,6}, Jens-Peter Reese⁴, Peter Heuschmann^{4,17,18}, André Karch^{&3}

Supplementary material 2: Ad hoc targeted literature synthesis

Figure S1: Flow chart of the literature search

Figure SF2-SF36: Forest plots

Table S1: Research questions of the systematic review (P Population, I (E) Intervention (Exposure), C Comparator, O Outcome, S Study design)

Table S2: Characteristics of the included studies from the review (n=90)

Table S3: Overview of protective effects (VE, vaccine effectiveness) against SARS-CoV-2 found in the literature: General population (adults > 18 years)

Table S4: Overview of protective effects (VE, vaccine effectiveness) against SARS-CoV-2 found in the literature: Older adults (>60 years)

Table S5: Overview of protective effects (VE, vaccine effectiveness) against SARS-CoV-2 found in the literature: Children and adolescents (5-17 years)

Table S6 Forest Plots: Stratification of study results

Table S7: List of figures of forest plots (SF2-SF36)

Table S8: Excluded primary studies with reason for exclusion (n=48)

Analogous to the current communication of the Robert Koch Institute as well as existing systematic reviews, meta-analyses, compilations of individual studies, and selected individual studies of the last few weeks, a translation of the antibody responses into protective profiles was also carried out in IMMUNE BRIDGE by means of a targeted literature synthesis on the protective effect of different exposure regimens and using epidemiological accompanying data as described above. This interpretation is exploratory and only usable under strong assumptions.

Targeted literature synthesis on the protective effect of different exposure combinations (summary)
 Within the framework of IMMUNE BRIDGE, a targeted literature synthesis was carried out. The aim was to provide a systematic overview based on the currently available studies of the protection against infection and severe illness by the different omicron variants depending on various combinations of SARS-CoV-2 immunity by vaccination and/or previous infection. Table S1 shows the research question according to the PICOS scheme. The focus was on vaccines licensed in Germany (Comirnaty/BNT162b2; Spikevax/mRNA-1273; Vaxzevria/ChAdOx1nCoV-19; JCOVDEN; Nuvaxovid). Risk groups such as chronically ill or immunosuppressed persons were explicitly included. Studies that exclusively examine healthcare workers or pregnant women were excluded.

Supplement 2 Table S1: Research questions of the systematic review (P Population, I (E) Intervention (Exposure), C Comparator, O Outcome, S Study design)

P	General population of all ages, people at increased risk of severe COVID-19 disease
I (E)	Different combinations of vaccination against SARS-CoV-2, infection with SARS-CoV-2, and seroprevalence of antibodies against S and N antigen of SARS-CoV-2
C	Individuals without vaccination/with lower numbers of vaccinations, without previous SARS-CoV-2 infection, without SARS-CoV-2 antibodies
O	Asymptomatic or symptomatic infection, severe COVID-19 disease (hospital admission, intensive care therapy), death from omicron variant
S	Randomised controlled trials, observational studies, population- or hospital-based studies

Studies were identified via the VIEW-hub (last accessed on December 1, 2022), through which the International Vaccine Access Center, the Johns Hopkins Bloomberg School of Public Health, the World Health Organization, and the Coalition for Epidemic Preparedness Innovations provide a weekly online compilation of vaccine effectiveness studies based on a systematic search of preprint and published literature. A data extraction table was used to systematically collect information on study design, setting, population, and results on vaccine effectiveness (VE). The data was extracted by one person and checked by a second person. The data were synthesized qualitatively; a subsequent meta-analysis was not performed due to the great heterogeneity between the studies. The results are presented in tables (summary of the ranges of the point estimates) and in forest plots.

Data were stratified by several parameters:

- age group (children/adolescents, adults 18-60 years, adults 60+)
- number of past vaccinations and/or infections
- reference group (not vaccinated, less vaccinated than comparison group)
- outcome (infection, severe disease, death)
- comorbidities (general population vs. diseased)
- days post exposure (=last vaccination or infection: < 14, 14-90, 90-180, > 180 Tage)

Results


In total, we included 90 studies, (see flow chart in Supplement 2 Figure S1), of those 24 studies examined children and adolescents, 53 adults above 18 years, and 28 adults above 60 years. Supplement 2 Table S2 provides an overview of the characteristics of the studies. The most frequently used study design was the test-negative case-control design, followed by retrospective cohort studies that mostly used registered or health claim based data. The older the study populations were, the more they examined higher exposure groups, and outcomes on severe disease or death. Almost half of the studies were published as preprints. Studies on children and adolescents mainly came from North

America (n=9), Asia and Europe (each n=5). Studies on adults predominantly were from the US (n=24), followed by Europe and Asia (each n=11), among the Asian studies five came from Quatar. Studies on older adults mostly took place in North Amerika (each n=5 in the US, and Canada) and Israel (n=6)

There is a high degree of heterogeneity due to differences in populations, vaccines and vaccine combinations, number of vaccinations, time period after last vaccination, survey of exposure (self-reported, documented, PCR test, antigen test, antibody test), definition of outcome (asymptomatic, positive test, severe disease, hospitalisation, intensive care treatment), study design (prospective or retrospective cohort study, case-control study, test-negative case-control study), analysis procedure, and consideration of covariates. Supplement 2 Tables S3, S4 and S5 qualitatively summarise the results on vaccine effectiveness from the primary studies identified so far for the different time periods after last exposure. Detailed results are presented in forest plots (Figures SF2-36) that are stratified by outcome, population group, exposure and reference group.

From the qualitative synthesis of results from studies on adult populations without special attention to risk groups, there is evidence of increasing protection analogous to the defined four categories based on vaccination, infection, and antibody status. With the same vaccination or immune status, there is a higher protection against severe COVID-19 diseases compared to a/symptomatic infections. Protection is highest 14 days to 3 months after the last exposure and then decreases again. This waning effect seems to be higher in older adults and higher for protection from infections rather than from severe course of disease. Compared to previously published systematic reviews, the added value of this review lies in the timeliness and number of identified studies, the differentiation of infection protection according to the time period after the last exposure, different reference groups, and, in particular, the consideration of different age groups.

Supplement 2 Figure S1: Flow chart of the literature search



¹ <https://view-hub.org/covid-19/effectiveness-studies>

² Health care workers, prisoners, pregnant people, infants

³ CoronaVac, Ad5-nCoV, BBIBP-CorV

⁴ Letter, Editorial, Correspondence, Report, Comment

⁵ before 12.02.2022 (RKI Review)

⁶ Multiple outcomes possible

Supplement 2 Table S2: Characteristics of the included studies from the review (n=90)

		Children and adolescents	Adults 18+	Adults 60+
		n	n	n
Total ¹		24	53	28
Country	USA	5	24	5
	Canada	4	3	5
	Argentina	2	1	
	Brazil	1	1	
	Chile		1	
	Hongkong	1	2	3
	Israel	2	1	6
	Quatar	1	5	
	Japan	1	2	1
	Singapore	2	1	
	UK, Scotland	2	3	3
	Sweden	1		
	Finland			1
	Norway	1		
	Denmark		4	1
	Czech		1	
	Italy	1		1
	France		1	
	Iceland		1	
	Spain		1	1
	Portugal			1
	Australia		1	
Exposure ²	3+	2	16	16
	3	9	52	21
	1-3	24	35	15
Outcome ²	Infection	18	33	19
	Severe disease	11	37	21
	Death	1	9	9
Preprint		10	28	13
Study design	Prospective cohort	2	4	2
	Retrospective cohort	8	16	9
	Case control study		2	3
	Test negative design (CCS)	13	30	11
	Target trial emulation, cohort	1	1	3

¹Total sum of included studies is n=90, calculated sum exceeds this due to some studies examining more than one subpopulation, i.e. children/adolescents, adults 18+, or adults 60+.

² Multiple answers possible

Supplement 2 Table S3: Overview of protective effects (VE, vaccine effectiveness) against SARS-CoV-2 found in the literature: General population (adults > 18 years)

Exposure	VE ³ against	VE no information ⁴	VE 0<14 days	VE 14-90 days	VE 91-180 days	VE >180 days
3+ Exposures	Infection ²	34-83% (n=5) ⁵ 47-96% (n=2) ⁶	36% (n=1)	20-92% (n=4) ⁵ 43-81% (n=1) ⁶	5-82% (n=4) ⁵ -38-66% (n=2) ⁶	
	Severe Course ¹	68-100% (n=5) ⁵		44-98% (n=5) ⁵	37-86% (n=2) ⁵	
	Death	81% (n=1) ⁵				
3 Exposures	Infection ²	-7-78% (n=16) ⁵ -4-96% (n=8) ⁶	18-69% (n=6) ⁵	1-91% (n=17) ⁵ -8-91% (n=8) ⁶	5-67% (n=8) ⁵ -23-62% (n=4) ⁶	-25-55% (n=3) ⁵ -20-50% (n=3) ⁶
	Severe Course ¹	31-99% (n=9) ⁵ 44-89% (n=5) ⁷	65-96% (n=4) ⁵	31-97% (n=10) ⁵ 44-98% (n=4) ⁷	29-95% (n=14) ⁵ 45-83% (n=2) ⁷	31-88% (n=3) ⁵ 84-89% (n=1) ⁷
	Death	87-98% (n=3) ⁵ 75-86% (n=1) ⁷	71-86% (n=1) ⁵	78-88% (n=3) ⁵ 75-99% (n=2) ⁷	74-87% (n=2) ⁵	77% (n=1) ⁵
1-3 Exposures	Infection ²	-46-65% (n=12) ⁵	10-23% (n=2) ⁵	8-55% (n=13) ⁵	1-54% (n=10) ⁵	-14-52% (n=11) ⁵
	Severe Course ¹	33-86% (n=11) ⁵		-9-96% (n=15) ⁵	24-87% (n=14) ⁵	12-92% (n=9) ⁵
	Death	66-90% (n=4) ⁵	-9-29% (n=1) ⁵	60-62% (n=2) ⁵	57-70% (n=1) ⁵	49-57% (n=2) ⁵

¹Different definitions were used for severe course: Hospitalization, treatment in intensive care, and/or death.

²Different definitions were used for infection: any, symptomatic, documented

³VE, Vaccine effectiveness; Range of point estimates of n included studies is provided, stratified for days post exposure

⁴No information on time after last exposure

⁵Reference group: no exposure (vaccination and/or infection)

⁶Reference group: 3 exposures

⁷Reference group: 2 exposures

Supplement 2 Table S4: Overview of protective effects (VE, vaccine effectiveness) against SARS-CoV-2 found in the literature: Older adults (>60 years)

Exposure	VE ³ against	VE no information ⁴	VE <14 days	VE 14-90 days	VE 91-180 days	VE >180 days
3+ Exposures	Infection ²	49-81% (n=2) ⁵ 36% (n=1) ⁶	33-58% (n=2) ⁶	19-69% (n=2) ⁵ 8-81% (n=7) ⁶	36-60% (n=1) ⁵ -5-18% (n=1) ⁶	18-44% (n=1) ⁵ -24--15% (n=1) ⁶
	Severe Course ¹	86% (n=1) ⁵ 64-72% (n=2) ⁶	86-98% (n=1) ⁵ 58% (n=1) ⁶	47-94% (n=4) ⁵ 8-89% (n=8) ⁶	78-89% (n=2) ⁵ 23-28% (n=1) ⁶	74% (n=1) ⁵ 6% (n=1) ⁶
	Death	49-82% (n=1) ⁵ 56-78% (n=3) ⁶		76-90% (n=2) ⁶		
3 Exposures	Infection ²	48-67% (n=2) ⁵ 30-47% (n=3) ⁷	58-66% (n=1) ⁵	-27-76% (n=6) ⁵ 54-58% (n=1) ⁷	23-56% (n=3) ⁵	
	Severe Course ¹	47-91% (n=5) ⁵ 16-64% (n=3) ⁷	66-95% (n=2) ⁵	51-98% (n=8) ⁵ 57-68% (n=1) ⁷	38-91% (n=6) ⁵ 65-66% (n=1) ⁷	75-85% (n=1) ⁵ 68% (n=1) ⁷
	Death	64-98% (n=3) ⁵ 13-86% (n=3) ⁷		96-98% (n=1) ⁵		
1-3 Exposures	Infection ²	3-79% (n=3) ⁵		-70-56% (n=3) ⁵	24-46% (n=2) ⁵	4-20% (n=2) ⁵
	Severe Course ¹	39-82% (n=4) ⁵		45-98% (n=5) ⁵	31-92% (n=3) ⁵	46-84% (n=3) ⁵
	Death	51-91% (n=3) ⁵		68-93% (n=1) ⁵		

¹Different definitions were used for severe course: Hospitalization, treatment in intensive care, and/or death.

²Different definitions were used for infection: any, symptomatic, documented

³VE, Vaccine effectiveness; Range of point estimates of n included studies is provided, stratified for days post exposure

⁴No information on time after last exposure

⁵Reference group: no exposure (vaccination and/or infection)

⁶Reference group : 3 exposures

⁷Reference group : 2 exposures

Supplement 2 Table S5: Overview of protective effects (VE, vaccine effectiveness) against SARS-CoV-2 found in the literature: Children and adolescents (5-17 years)

Exposure	VE ³ against	VE no information ⁴	VE <14 days	VE 14-90 days	VE 91-180 days	VE >180 days
3+ Exposures	Infection ²	96% (n=1) ⁵	78-90% (n=1) ⁵	80-90% (n=1) ⁵		
	Severe Course ¹					
	Death					
3 Exposures	Infection ²	38-79% (n=5) ⁵	55-96% (n=5) ⁵	30-91% (n=4) ⁵ 76% (n=1) ⁶	34-96% (n=1) ⁵	29-76% (n=1) ⁵
	Severe Course ¹					
	Death					
1-3 Exposures	Infection ²	-2-78% (n=9) ⁵	-18-88% (n=6) ⁵	-34-85% (n=15) ⁵	-25-86% (n=13) ⁵	-2-90% (n=4) ⁵
	Severe Course ¹	33-85% (n=10) ⁵	21-65% (n=1) ⁵	34-94% (n=8) ⁵	-3-92% (n=5) ⁵	16-88% (n=3) ⁵
	Death	98% (n=1) ⁵				

¹ Different definitions were used for severe course: Hospitalization, treatment in intensive care, and/or death.

² Different definitions were used for infection: any, symptomatic, documented

³ VE, Vaccine effectiveness; Range of point estimates of n included studies is provided, stratified for days post exposure

⁴ No information on time after last exposure

⁵ Reference group: no exposure (vaccination and/or infection)

⁶ Reference group: 3 exposures

Forest Plots

Supplement 2 Table S6: Stratification of study results

Feature	Category	Explanation
Outcome	Infection	Any, a-/symptomatic, documented, confirmed
	Severe disease	Hospitalisation, intensive care use , death
	Death	All cause mortality, COVID-19 related mortality (within 30 days after infection)
Population	General population	Adults 18-59 years, all ages (studies without age specification)
	Older adults	60+ years
	Children and adolescents	5-17 years
Exposure	3+ exposures	More than 3 exposures (vaccination or infection, thereof one in 2022)
	3 exposures	3 exposures (vaccination or infection)
	1-3 exposures	1-2 exposures (vaccination or infection)
Reference	Unvaccinated	No vaccination and/or infection
	Less exposures	Less vaccinations/infections
Time after last exposure	No information	No specification of time after last exposure
	<14 days post exposure	Within 2 weeks after exposure
	14-90 days post exposure	Up to ~ 3 months after exposure
	91-180 days post exposure	~ 3 to 6 months after exposure
	>180 days post exposure	More than ~ 6 months after exposure


Multiple naming of a study within a forest plot is possible, due to further stratification within the study, e.g. for: Vaccine type, Omicron subvariant, combination of exposures, more than one time periode within a category of time after exposure, reported outcome

Supplement 2 Table S7: List of figures of forest plots:

SF2	Infection: General population (adults 18+ years), Exposure 3+, Reference unvaccinated (n=9)
SF3	Infection: General population (18+ years); Exposure 3+, Reference less exposures (3 exposures) (n=4)
SF4	Infection: General population (adults 18+ years), Exposure 3, Reference unvaccinated (n=24)
SF5	Infection: General population (adults 18+), Exposure 3, Reference less exposures (2 exposures) (n=14)
SF6	Infection: General population (adults 18+), Exposure 1-3, Reference unvaccinated (n=21)
SF7	Infection: Older adults (60+ years), Exposure 3+, Reference unvaccinated (n=4)
SF8	Infection: Older adults (60+ years), Exposure 3+, Reference less exposures (3 exposures) (n=8)
SF9	Infection: Older adults (60+years), Exposure 3, Reference unvaccinated (n=9)
SF10	Infection: Older adults (60+ years), Exposure 3, Reference less exposures (2 exposures) (n=4)
SF11	Infection: Older adults (60+ years), Exposure 1-3, Reference unvaccinated (n=8)
SF12	Infection: Children and adolescents (5-17 years), Exposure 3+, Reference unvaccinated (n=2)
SF13	Infection: Children and adolescents (5-17 years), Exposure 3, Reference unvaccinated (n=7)
SF14	Infection: Children and adolescents (5-17 years), Exposure 3, Reference less exposures (2 exposures) (n=1)
SF15	Infection: Children and adolescents (5-17 years), Exposure 1-3, Reference unvaccinated (n=17)
SF16	Severe disease: General population (adults 18+ years), Exposure 3+, Reference unvaccinated (n=10)
SF17	Severe disease: General population (adults 18+ years), Exposure 3, Reference unvaccinated (n=24)


SF18	Severe disease: General population (adults 18+), Exposure 3, Reference less exposures (2 exposures) (n=9)
SF19	Severe disease: General population (adults 18+ years), Exposure 1-3, Reference unvaccinated (n=23)
SF20	Severe disease: Older adults (60+ years), Exposure 3+, Reference unvaccinated (n=4)
SF21	Severe disease: Older adults (60+ years), Exposure 3+, Reference less exposures (3 exposures) (n=10)
SF22	Severe disease: Older adults (60+ years), Exposure 3, Reference unvaccinated (n=12)
SF23	Severe disease: Older adults (60+ years), Exposure 3, Reference less exposures (2 exposures) (n=4)
SF24	Severe disease: Older adults (60+ years), Exposure 1-3, Reference unvaccinated (n=11)
SF25	Severe disease: Children and adolescents (5-17 years), Exposure 3, Reference vaccinated (n=4)
SF26	Severe disease: Children and adolescents (5-17 years), Exposure 1-3, Reference unvaccinated (n=11)
SF27	Death: General population (adults 18+ years), Exposure 3+, Reference unvaccinated (n=1)
SF28	Death: General population (adults 18+ years), Exposure 3, Reference unvaccinated (n=6)
SF29	Death: General population (adults 18+ years), Exposure 3, Reference less exposures (2 exposures) (n=3)
SF30	Death: General population (adults 18+ years), Exposure 1-3, Reference unvaccinated (n=4)
SF31	Death: Older adults (60+ years), Exposure 3+, Reference unvaccinated (n=1)
SF32	Death: Older adults (60+ years), Exposure 3+, Reference less exposures (3 exposures) (n=5)
SF33	Death: Older adults (60+ years), Exposure 3, Reference unvaccinated (n=4)
SF34	Death: Older adults (60+ years), Exposure 3, Reference less exposures (2 exposures) (n=3)
SF35	Death: Older adults (60+ years), Exposure 1-3, Reference unvaccinated (n=4)
SF36	Death: Children and adolescents (5-17 years), Exposure 1-3, Reference unvaccinated (n=1)

SF2: Infection: General population (adults 18+ years), Exposure 3+, Reference unvaccinated (n=9)



Author (Date)	VE in %	lower CI 95%	upper CI 95%
91-180 days post exposure			
Šmíd (25.02.2022)	82,0	72,0	89,0
Šmíd (25.02.2022)	48,0	45,0	52,0
Chemaitlely (01.11.2022)	47,0	37,0	56,0
Tseng (01.10.2022)	17,3	-45,3	62,6
Lin (26.09.2022)	12,4	4,6	19,5
Tseng (01.10.2022)	6,3	-66,3	70,4
Tseng (01.10.2022)	5,0	-56,9	61,1
14-90 days post exposure			
Šmíd (25.02.2022)	92,0	89,0	94,0
Tseng (01.10.2022)	75,7	34,7	91,0
Šmíd (25.02.2022)	74,0	73,0	75,0
Tseng (01.10.2022)	64,3	50,7	74,2
Lin (26.09.2022)	53,9	50,8	56,8
Tseng (01.10.2022)	51,1	35,5	63,0
Tseng (01.10.2022)	50,9	13,4	72,1
Link-Gelles (22.11.2022)	43,0	39,0	46,0
Tseng (01.10.2022)	36,7	13,6	53,6
Lin (26.09.2022)	32,3	28,5	35,9
Tseng (01.10.2022)	30,8	-9,2	56,5
Link-Gelles (22.11.2022)	28,0	20,0	34,0
Lin (26.09.2022)	20,3	15,2	25,2
<14 days post exposure			
Lind (25.04.2022)	36,3	-71,8	76,4
No information			
Carazo (03.05.2022)	83,0	81,0	84,0
Castillo (21.04.2022)	81,0	80,0	81,0
Altarawneh (15.06.2022)	76,3	71,7	80,1
Tseng (01.10.2022)	55,7	44,2	64,9
Tseng (01.10.2022)	54,8	25,1	72,7
Lind (25.04.2022)	45,8	20,0	63,2
Tseng (01.10.2022)	34,3	12,2	50,8


SF3: Infection: General population (18+ years); Exposure 3+, Reference less exposures (3 exposures) (n=4)



Author (date)	VE in %	lower CI 95%	upper CI 95%
91-180 days post exposure			
Tseng (01.10.2022)	66,1	22,1	85,3
Tseng (01.10.2022)	48,4	-24,2	79,8
Tseng (01.10.2022)	42,4	-48,5	82,9
Chemaitlely (15.11.2022)	39,8	35,7	43,6
Chemaitlely (15.11.2022)	23,2	-4,5	43,7
Chemaitlely (01.11.2022)	-38,0	-65,0	-16,0
14-90 days post exposure			
Tseng (01.10.2022)	80,8	49,6	92,7
Tseng (01.10.2022)	64,3	52,0	73,5
Tseng (01.10.2022)	56,9	28,8	73,9
Tseng (01.10.2022)	55,4	42,9	65,1
Tseng (01.10.2022)	49,8	35,3	61,1
Tseng (01.10.2022)	43,2	12,4	63,1
No information			
Hansen (18.07.2022)	96,3	95,8	96,7
Hansen (18.07.2022)	93,6	92,1	94,8
Hansen (18.07.2022)	77,2	72,2	81,3
Hansen (18.07.2022)	74,5	68,7	79,2
Hansen (18.07.2022)	65,4	49,8	76,2
Tseng (01.10.2022)	63,0	42,5	76,2
Tseng (01.10.2022)	59,6	50,9	66,8
Tseng (01.10.2022)	48,5	35,0	59,1
Hansen (18.07.2022)	46,9	27,0	61,3


SF4:Infection: General population (adults 18+ years), Exposure 3, Reference unvaccinated (n=24)

Author (Date)	VE in %	lower CI 95%	upper CI 95 %	Hansen (30.03.2022)	41,0	40,3	41,7
				Hansen (30.03.2022)	41,0	40,5	41,5
				Kirsbom (01.05.2022)	40,8	18,6	56,9
				Lin (26.09.2022)	40,6	39,7	41,6
				Chemaitlely (02.06.2022)	37,3	25,4	47,3
				Chemaitlely (02.06.2022)	32,6	17,8	44,8
				Chemaitlely (02.06.2022)	31,5	20,3	41,1
				Šmíd (25.02.2022)	21,0	19,0	23,0
				Tseng (01.10.2022)	0,7	-53,6	54,2
>180 days post exposure				<14 days post exposure			
Tseng (01.10.2022)	54,9	35,6	68,4	Arashiro (03.08.2022)	69,0	50,0	81,0
Wang (25.03.2022)	50,0	45,0	55,0	Kirsbom (01.05.2022)	61,2	40,9	74,9
Lind (25.04.2022)	34,0	18,5	46,5	Kirsbom (01.05.2022)	58,2	57,0	59,4
Tseng (01.10.2022)	-16,4	-35,8	8,2	Lind (25.04.2022)	38,1	18,6	52,9
Tseng (01.10.2022)	-17,9	-29,6	-4,2	Buchan (22.09.2022)	36,0	29,0	43,0
Tseng (01.10.2022)	-24,9	-32,3	-16,7	Castillo (21.04.2022)	35,0	34,0	36,0
91-180 days post exposure				Lind (25.04.2022)	33,2	3,7	53,6
Tseng (01.10.2022)	67,3	62,0	71,9	Chemaitlely (02.06.2022)	19,7	-9,7	41,2
Chemaitlely (01.11.2022)	57,0	52,0	62,0	Chemaitlely (02.06.2022)	17,7	2,5	30,6
Gram (01.09.2022)	52,3	48,0	56,2	No information			
Gram (01.09.2022)	51,3	49,8	52,7	Arashiro (03.08.2022)	78,0	67,0	86,0
Castillo (21.04.2022)	50,0	48,0	51,0	Tseng (01.10.2022)	76,6	74,4	78,6
Hansen (30.03.2022)	40,5	38,9	42,2	Carazo (03.05.2022)	73,0	72,0	73,0
Hansen (30.03.2022)	38,6	37,7	39,5	Mimura (08.10.2022)	71,8	60,1	80,1
Hansen (30.03.2022)	37,9	33,4	42,0	Carazo (03.05.2022)	68,0	67,0	70,0
Kirsbom (01.05.2022)	37,2	-44,1	72,1	Young-Xu (03.08.2022)	64,0	63,0	65,0
Hansen (30.03.2022)	36,9	34,8	38,9	Kim (10.04.2022)	62,0	48,0	72,0
Kirsbom (01.05.2022)	30,6	26,8	34,3	Risk (16.08.2022)	57,0	51,0	62,0
Cerqueira-Silva (14.04.2022)	29,2	25,0	33,1	Lind (25.04.2022)	56,9	52,1	61,2
Tseng (01.10.2022)	23,2	-12,3	48,3	Mimura (08.10.2022)	56,5	46	65
Chemaitlely (02.06.2022)	21,9	7,7	33,9	Altarawneh (15.06.2022)	55,5	51,8	59,0
Tseng (01.10.2022)	20,7	-1,6	38,2	Altarawneh (15.06.2022)	54,0	50,4	57,3
Lin (26.09.2022)	11,7	9,9	13,5	Risk (16.08.2022)	35,0	29,0	41,0
Tseng (01.10.2022)	10,8	0,8	19,8	Tseng (01.10.2022)	-2,2	-10,5	6,4
Cerqueira-Silva (14.04.2022)	5,4	3,2	7,5	Tseng (01.10.2022)	-7,0	-19,8	7,2
14-90 days post exposure				Tseng (01.10.2022)	-7,2	-27,9	16,4
Tseng (01.10.2022)	90,6	30,6	98,7				
Šmíd (25.02.2022)	86,0	85,0	88,0				
Tseng (01.10.2022)	85,8	82,7	88,3				
Šmíd (25.02.2022)	82,0	75,0	87,0				
Šmíd (25.02.2022)	77,0	76,0	78,0				
Tseng (01.10.2022)	76,3	73,9	78,6				
Tseng (01.10.2022)	72,6	-54,7	96,6				
Tseng (21.04.2022)	71,6	69,7	73,4				
Castillo (21.04.2022)	67,0	67,0	68,0				
Rennert (07.05.2022)	66,4	46,1	79,0				
Wang (25.03.2022)	65,0	63,0	66,0				
Kirsbom (01.05.2022)	63,8	63,0	64,5				
Lin (26.09.2022)	62,9	62,3	63,3				
Buchan (22.09.2022)	61,0	56,0	65,0				
Tseng (01.10.2022)	61,0	27,6	79,0				
Castillo (21.04.2022)	59,0	59,0	60,0				
Castillo (21.04.2022)	58,0	57,0	59,0				
Kirsbom (01.05.2022)	57,3	56,4	58,2				
Tseng (01.10.2022)	57,0	26,5	75,0				
Šmíd (25.02.2022)	56,0	55,0	56,0				
Chemaitlely (02.06.2022)	55,5	49,3	61,0				
Gram (01.09.2022)	55,1	54,6	55,5				
Chemaitlely (02.06.2022)	53,7	39,6	64,6				
Chemaitlely (02.06.2022)	53,7	41,5	63,3				
Cerqueira-Silva (14.04.2022)	53,4	51,4	55,3				
Kirsbom (01.05.2022)	53,0	42,6	61,6				
Gram (01.09.2022)	52,7	51,8	53,6				
Kirsbom (01.05.2022)	51,7	38,9	61,8				
Chemaitlely (02.06.2022)	51,5	45,0	57,2				
Gram (01.09.2022)	51,1	50,4	51,7				
Tsang (25.08.2022)	50,9	31,0	65,0				
Lin (26.09.2022)	50,8	50,1	51,5				
Hansen (30.03.2022)	47,9	47,4	48,3				
Hansen (30.03.2022)	47,7	47,0	48,3				
Tseng (21.04.2022)	47,4	40,5	53,5				
Kirsbom (01.05.2022)	46,4	45,0	47,8				
Hansen (30.03.2022)	45,5	44,9	46,2				
Rennert (07.05.2022)	45,4	30,0	57,4				
Šmíd (25.02.2022)	45,0	44,0	46,0				
Chemaitlely (02.06.2022)	43,6	36,5	49,9				
Hansen (30.03.2022)	43,5	42,2	44,7				
Cerqueira-Silva (14.04.2022)	42,3	41,6	42,9				
Tsang (25.08.2022)	41,4	23,2	55,2				
Tseng (01.10.2022)	41,2	28,3	51,8				
Link-Gelles (22.11.2022)	41,0	31,0	46,0				




SF5: Infection: General population (adults 18+), Exposure 3, Reference less exposures (2 exposures) (n=14)

Author (date)	VE in %	lower CI 95%	upper CI 95%	loannou (16.06.2022)	46,5	44,1	48,7
>180 days post exposure							
Tseng (01.10.2022)	50,0	28,4	65,1	loannou (16.06.2022)	44,6	42,5	46,6
Ng (26.08.2022)	14,6	11,0	18,0	loannou (16.06.2022)	44,3	42,2	46,3
Chemaitlely (15.11.2022)	14,4	7,3	20,9	loannou (16.06.2022)	43,3	41,4	45,4
Ng (26.08.2022)	9,7	2,7	16,3	loannou (16.06.2022)	42,3	40,6	43,9
Ng (26.08.2022)	3,7	0,0	7,2	loannou (16.06.2022)	39,6	36,9	42,1
Ng (26.08.2022)	-2,8	-5,4	0,3	loannou (16.06.2022)	39,0	36,4	41,6
Tseng (01.10.2022)	-13,1	-36,3	15,6	Norddahl (01.03.2022)	36,4	33,3	39,4
Tseng (01.10.2022)	-13,6	-23,4	-2,5	Norddahl (01.03.2022)	30,0	14,0	43,0
Tseng (01.10.2022)	-17,1	-31,4	0,2	Norddahl (01.03.2022)	27,0	9,0	41,0
Chemaitlely (15.11.2022)	-20,3	-55,0	29,0	Butt (03.05.2022)	19,0	17,0	22,0
91-180 days post exposure							
Tseng (01.10.2022)	62,0	55,5	67,5	Norddahl (01.03.2022)	14,0	-37,0	47,0
Chemaitlely (15.11.2022)	41,2	40,1	42,3	Liu (21.06.2022)	13,6	4,1	22,1
Chemaitlely (15.11.2022)	41,1	40,0	42,1	Tseng (01.10.2022)	9,0	-21,0	32,0
Chemaitlely (15.11.2022)	38,5	37,3	39,8	Norddahl (01.03.2022)	7,0	-16,0	25,0
Tseng (01.10.2022)	29,1	-6,9	53,2	Tseng (01.10.2022)	6,9	4,8	9,0
Tseng (01.10.2022)	22,5	12,8	31,2	Tseng (01.10.2022)	-1,1	-26,1	24,5
Patalon (09.06.2022)	18,3	15,2	21,2	Tseng (01.10.2022)	-3,9	-19,7	13,0
Tseng (01.10.2022)	18,0	-6,7	37,3				
Patalon (09.06.2022)	16,0	12,3	19,5				
Butt (03.05.2022)	-9,0	-22,0	2,0				
Butt (03.05.2022)	-23,0	-65,0	9,0				
14-90 days post exposure							
Tseng (01.10.2022)	91,0	33,6	98,8				
Tseng (01.10.2022)	81,0	77,0	84,4				
Tseng (01.10.2022)	71,8	-55,7	96,5				
Andersson (29.11.2022)	69,8	69,2	70,5				
Tseng (01.10.2022)	68,8	65,5	71,9				
Andersson (29.11.2022)	65,1	62,8	67,4				
Tseng (01.10.2022)	63,6	32,3	80,4				
Patalon (09.06.2022)	59,4	54,9	63,5				
Chemaitlely (15.11.2022)	57,1	55,9	58,3				
Tseng (01.10.2022)	53,3	18,9	73,1				
Monge (02.06.2022)	51,3	50,2	52,4				
Monge (02.06.2022)	49,9	48,6	51,3				
Tseng (01.10.2022)	48,5	36,7	58,1				
Andersson (29.11.2022)	47,9	41,5	54,3				
Patalon (09.06.2022)	43,2	38,2	47,8				
Ng (26.08.2022)	41,3	39,4	43,1				
Butt (03.05.2022)	40,0	35,0	44,0				
Andersson (29.11.2022)	39,5	37,2	41,8				
Gonzales (27.09.2022)	36,0	33,0	39,0				
Ng (26.08.2022)	35,6	32,8	38,3				
Ng (26.08.2022)	34,9	33,0	36,8				
Ng (26.08.2022)	31,7	30,0	33,4				
Andersson (29.11.2022)	31	25,5	36,6				
Butt (03.05.2022)	30,0	23,0	36,0				
Patalon (09.06.2022)	29,1	26,1	32,0				
Ng (26.08.2022)	26,3	24,2	28,3				
Butt (03.05.2022)	24,0	17,0	31,0				
Ng (26.08.2022)	23,4	20,7	26,1				
Andersson (29.11.2022)	23	21,3	24,8				
Butt (03.05.2022)	23,0	18,0	27,0				
Ng (26.08.2022)	18,3	15,9	20,7				
Butt (03.05.2022)	12,0	1,0	21,0				
Ng (26.08.2022)	11,9	9,7	14,0				
Gonzales (27.09.2022)	8,0	-4,0	19,0				
Andersson (29.11.2022)	4,2	0,2	8,2				
Andersson (29.11.2022)	0,8	-1,0	2,6				
Butt (03.05.2022)	0,0	-7,0	6,0				
Tseng (01.10.2022)	-8,2	-57,8	50,0				
No information							
Norddahl (01.03.2022)	96,0	25,0	64,0				
Liu (21.06.2022)	93,8	92,9	94,5				
Tseng (01.10.2022)	70,3	67,4	73,0				
Petrie (16.04.2022)	70,0	51,0	81,0				
Petrie (16.04.2022)	66,0	46,0	79,0				
Mimura (08.10.2022)	64,2	49,9	74,4				
Norddahl (01.03.2022)	50,0	34,0	62,0				
Abu-Raddad (12.05.2022)	49,4	47,1	51,6				
Mimura (08.10.2022)	48,3	36,4	57,9				
Abu-Raddad (12.05.2022)	47,3	40,7	53,3				
Norddahl (01.03.2022)	47,0	36,0	56,0				




SF6: Infection: General population (adults 18+), Exposure 1-3, Reference unvaccinated (n=21)

Author (Date)	VE in %	upper CI 95%	lower CI 95%	Lind (25.04.2022)	23,1	15,2	30,2
>180 days post exposure							
Arashiro (03.08.2022)	52,0	37,0	63,0	Chemaitlely (02.06.2022)	9,8	-94,1	58,1
Lin (26.09.2022)	50,7	46,3	54,7	Chemaitlely (02.06.2022)	9,5	-39,8	41,3
Lin (26.09.2022)	49,0	46,4	51,4	No information			
Lin (26.09.2022)	47,2	45,8	48,5	Carazo (03.05.2022)	65,0	63,0	67,0
Lin (26.09.2022)	37,5	36,0	39,0	Lin (26.09.2022)	52,3	49,3	55,1
Lin (26.09.2022)	30,9	28,9	32,9	Castillo (21.04.2022)	51,0	50,0	52,0
Lin (26.09.2022)	30,6	29,1	32,0	Altarawneh (15.06.2022)	50,8	45,4	55,7
Lin (26.09.2022)	30,3	28,4	32,2	Altarawneh (15.06.2022)	50,2	38,1	59,9
Lin (26.09.2022)	26,4	24,6	28,2	Lin (26.09.2022)	46,4	45,3	47,5
Lind (25.04.2022)	15,3	10,4	20,2	Carazo (03.05.2022)	43,2	42,0	44,4
Lin (26.09.2022)	14,5	13,0	16,0	Carazo (03.05.2022)	42,0	41,0	44,0
Tseng (21.04.2022)	13,8	11,0	10,2	Wang (25.03.2022)	39,0	36,0	42,0
Šmid (25.02.2022)	13,0	11,0	14,0	Chemaitlely (02.06.2022)	31,4	12,5	46,3
Kim (10.04.2022)	11,0	-21,0	35,0	Arashiro (03.08.2022)	29,0	-32,0	62,0
Castillo (21.04.2022)	11,0	10,0	13,0	Mimura (08.10.2022)	21,2	11,0	30,3
Kirsbom (01.05.2022)	8,0	6,0	9,9	Kim (10.04.2022)	21,0	-6,0	41,0
Wang (25.03.2022)	7,0	4,0	10,0	Tseng (21.04.2022)	20,4	9,5	30,0
Tseng (21.04.2022)	5,9	0,4	11,0	Carazo (03.05.2022)	20,0	16,0	24,0
Buchan (22.09.2022)	2,0	-17,0	17,0	Risk (16.08.2022)	16,0	5,0	26,0
Buchan (22.09.2022)	1,0	-8,0	10,0	Mimura (08.10.2022)	15,8	7,9	23,1
Lin (26.09.2022)	0,8	-1,5	3,0	Young-Xu (03.08.2022)	12,0	10,0	15,0
Chemaitlely (02.06.2022)	-9,0	-14,5	-3,7	Chemaitlely (02.06.2022)	9,5	-39,9	41,5
Chemaitlely (02.06.2022)	-13,7	-21,3	-6,6	Altarawneh (15.06.2022)	-0,2	-5,5	4,9
91-180 days post exposure							
Arashiro (03.08.2022)	54,0	42,0	63,0	Altarawneh (15.06.2022)	-1,1	-7,1	4,6
Carazo (03.05.2022)	51,0	38,0	60,0	Altarawneh (15.06.2022)	-4,9	-16,4	5,4
Carazo (03.05.2022)	44,0	29,0	48,0	Risk (16.08.2022)	-6,0	-16,0	4,0
Carazo (03.05.2022)	44,0	38,0	48,0	Mimura (08.10.2022)	-24,4	-112,3	27,1
Chemaitlely (07.07.2022)	38,1	36,3	39,8	Mimura (08.10.2022)	-45,6	-111,4	0,3
Gram (01.09.2022)	31,3	30,3	32,4				
Hansen (30.03.2022)	27,4	26,2	28,5				
Castillo (21.04.2022)	26,0	24,0	27,0				
Tseng (21.04.2022)	23,5	14,4	30,0				
Hansen (30.03.2022)	23,3	21,1	25,5				
Chemaitlely (02.06.2022)	18,7	11,3	25,5				
Chemaitlely (02.06.2022)	16,3	9,7	22,5				
Castillo (21.04.2022)	16,0	15,0	17,0				
Buchan (22.09.2022)	15,0	8,0	22,0				
Hansen (30.03.2022)	13,2	12,3	14,2				
Gram (01.09.2022)	12,6	12,0	13,3				
Hansen (30.03.2022)	9,8	9,2	10,4				
Tsang (25.08.2022)	4,7	-23,5	26,6				
Castillo (21.04.2022)	3,0	2,0	4,0				
Tsang (25.08.2022)	1,1	-22,4	20,1				
14-90 days post exposure							
Arashiro (03.08.2022)	55,0	34,0	69,0				
Chemaitlely (02.06.2022)	47,8	40,8	53,9				
Kim (10.04.2022)	45,0	14,0	66,0				
Tseng (21.04.2022)	44,0	35,1	51,6				
Chemaitlely (02.06.2022)	43,2	15,0	62,1				
Castillo (21.04.2022)	43,0	41,0	45,0				
Šmid (25.02.2022)	43,0	42,0	44,0				
Gram (01.09.2022)	40,0	38,6	41,3				
Hansen (30.03.2022)	37,9	34,4	41,2				
Hansen (30.03.2022)	37,0	35,6	38,0				
Buchan (22.09.2022)	36,0	24,0	45,0				
Tsang (25.08.2022)	35,3	-4,2	59,8				
Gram (01.09.2022)	32,3	30,9	33,7				
Castillo (21.04.2022)	32,0	30,0	34,0				
Gram (01.09.2022)	31,9	30,7	33,0				
Lind (25.04.2022)	28,5	20,0	36,2				
Hansen (30.03.2022)	27,4	26,3	28,4				
Hansen (30.03.2022)	27,1	24,5	29,6				
Castillo (21.04.2022)	27,0	26,0	29,0				
Hansen (30.03.2022)	26,8	23,8	26,9				
Hansen (30.03.2022)	26,6	25,3	27,9				
Wang (25.03.2022)	26,0	22,0	30,0				
Rennert (07.05.2022)	25,6	-17,6	52,9				
Tsang (25.08.2022)	20,4	-30,9	51,6				
Buchan (22.09.2022)	12,0	3,0	21,0				
Castillo (21.04.2022)	12,0	9,0	14,0				
Rennert (07.05.2022)	7,7	-11,5	23,5				
<14 days post exposure							




SF7: Infection: Older adults (60+ years), Exposure 3+, Reference unvaccinated (n=4)




Author (Date)	VE in %	upper CI 95%	lower CI 95%
>180 days post exposure			
Grewal (30.09.2022)	44,0	24,0	59,0
Grewal (30.09.2022)	18,0	5,0	28,0
91-180 days post exposure			
Grewal (30.09.2022)	60,0	49,0	69,0
Grewal (30.09.2022)	56,0	41,0	67,0
Grewal (30.09.2022)	49,0	32,0	62,0
Grewal (30.09.2022)	42,0	36,0	48,0
Grewal (30.09.2022)	38,0	29,0	46,0
Grewal (30.09.2022)	36,0	26,0	44,0
14-90 days post exposure			
Grewal (30.09.2022)	69,0	61,0	75,0
Grewal (30.09.2022)	49,0	44,0	54,0
Link-Gelles (22.11.2022)	23,0	15,0	30,0
Link-Gelles (22.11.2022)	19,0	8,0	29,0
No information			
Carazo (03.05.2022)	81,0	75,0	86,0
Grewal (08.06.2022)	69,0	61,0	76,0
Grewal (08.06.2022)	49,0	43,0	54,0

SF8: Infection: Older adults (60+ years), Exposure 3+, Reference less exposures (3 exposures) (n=8)




Author (date)	VE in %	lower CI 95%	upper CI 95%
>180 days post exposure			
Grewal (30.09.2022)	-15,0	-49,0	11,0
Grewal (30.09.2022)	-24,0	-41,0	-9,0
91-180 days post exposure			
Grewal (30.09.2022)	18,0	1,0	32,0
Grewal (30.09.2022)	13,0	3,0	21,0
Grewal (30.09.2022)	10,0	-15,0	30,0
Grewal (30.09.2022)	7,0	-6,0	18,0
Grewal (30.09.2022)	3,0	-12,0	16,0
Grewal (30.09.2022)	-5,0	-35,0	18,0
14-90 days post exposure			
Breznik (29.06.2022)	81,0	70,0	88,0
Gazit (24.05.2022)	65,1	63,0	67,1
Gazit (24.05.2022)	64,0	61,1	66,3
Magen (13.04.2022)	61,0	58,0	64,0
Gazit (24.05.2022)	58,1	54,8	61,1
Gazit (24.05.2022)	55,0	50,6	58,9
Magen (13.04.2022)	52,0	49,0	54,0
Gazit (24.05.2022)	50,2	44,5	55,3
Breznik (29.06.2022)	48,0	1,0	73,0
Gazit (24.05.2022)	42,5	35,1	49,1
Grewal (30.09.2022)	36,0	26,0	44,0
Gazit (24.05.2022)	33,4	23,8	41,8
Fabiani (14.11.2022)	28,5	24,7	32,1
Mc Coneghy (30.09.2022)	25,8	1,2	44,3
Grewal (30.09.2022)	23,0	17,0	29,0
Gazit (24.05.2022)	22,0	4,9	36,1
Bar-On (05.04.2022)	9,2	0,0	16,7
Fabiani (14.11.2022)	7,6	-14,1	18,3
<14 days post exposure			
Gazit (24.05.2022)	57,7	55,6	59,7
Bar-On (05.04.2022)	33,3	33,3	37,5
No information			
Muhsen (23.06.2022)	36,0	31,0	40,0

SF9: Infection: Older adults (60+years), Exposure 3, Reference unvaccinated (n=9)




Author (Date)	VE in %	lower CI 95%	upper CI 95%
91-180 days post exposure			
Gram (01.09.2022)	56,0	53,7	58,1
Grewal (08.06.2022)	55,0	45,0	64,0
Gram (01.09.2022)	53,2	49,6	56,6
Grewal (30.09.2022)	51,0	42,0	60,0
Grewal (08.06.2022)	37,0	31,0	43,0
Grewal (30.09.2022)	34,0	28,0	39,0
Kirsbom (01.05.2022)	23,1	15,1	30,5
14-90 days post exposure			
Wan (17.10.2022)	75,6	73,2	77,8
Kirsbom (01.05.2022)	68,5	65,7	71,2
Grewal (08.06.2022)	62,0	51,0	71,0
Grewal (30.09.2022)	59,0	48,0	68,0
Gram (01.09.2022)	57,9	56,1	59,6
Gram (01.09.2022)	57,7	55,9	59,5
Gram (01.09.2022)	54,4	52,7	56,0
Kirsbom (01.05.2022)	54,1	50,5	57,5
Kirsbom (01.05.2022)	51,6	20,8	70,4
Wan (17.10.2022)	50,9	46,9	52,1
Kirsbom (01.05.2022)	44,5	22,4	60,2
Kirsbom (01.05.2022)	40,1	35,2	44,5
Grewal (08.06.2022)	39,0	33,0	45,0
Grewal (30.09.2022)	38,0	32,0	43,0
Link-Gelles (22.11.2022)	32,0	9,00	49,00
Tsang (25.08.2022)	-1,5	-101,0	48,7
Kirsbom (01.05.2022)	-27,2	-131,6	30,1
<14 days post exposure			
Kirsbom (01.05.2022)	66,1	16,6	86,3
Kirsbom (01.05.2022)	58,1	51,6	63,8
No information			
Carazo (03.05.2022)	67,0	60,0	73,0
Sharma (27.04.2022)	61,9	59,4	64,4
Sharma (27.04.2022)	47,8	45,2	50,3

SF10: Infection: Older adults (60+ years), Exposure 3, Reference less exposures (2 exposures) (n=4)




SF11: Infection: Older adults (60+ years), Exposure 1-3, Reference unvaccinated (n=8)




Author (Date)	VE in %	lower CI 95%	upper CI 95%
>180 days post exposure			
Kirsbom (01.05.2022)	19,5	11,7	26,6
Gram (01.09.2022)	4,4	-0,1	8,7
91-180 days post exposure			
Carazo (03.05.2022)	46,0	16,0	65,0
Gram (01.09.2022)	24,0	11,4	38,8
14-90 days post exposure			
Wan (17.10.2022)	56,2	53,8	58,5
Wan (17.10.2022)	46,2	42,1	50
Gram (01.09.2022)	39,9	26,3	50,9
Gram (01.09.2022)	39,0	27,6	48,7
Gram (01.09.2022)	25,2	9,0	38,6
Wan (17.10.2022)	20,3	18,4	22,1
Wan (17.10.2022)	19,2	16,2	22
Tsang (25.08.2022)	-39,3	-236,4	42,4
Tsang (25.08.2022)	-69,7	-353,1	36,5
No information			
Carazo (03.05.2022)	79,0	65,0	87,0
Sharma (27.04.2022)	39,5	35,8	43,0
Sharma (27.04.2022)	25,3	21,8	28,7
Grewal (08.06.2022)	23,0	1,0	40,0
Grewal (30.09.2022)	21,0	1,0	38,0
Grewal (08.06.2022)	6,0	-5,0	15,0
Grewal (30.09.2022)	3,0	-7,0	12,0

SF12: Infection: Children and adolescents (5-17 years), Exposure 3+, Reference unvaccinated (n=2)




SF13: Infection: Children and adolescents (5-17 years), Exposure 3, Reference unvaccinated (n=7)



Author (Date)	VE in %	lower CI 95%	upper CI 95%
>180 days post exposure			
Powell (22.08.2022)	76,1	65,3	83,6
Powell (22.08.2022)	63,6	46,0	75,5
Powell (22.08.2022)	28,9	-15,5	56,3
91-180 days post exposure			
Powell (22.08.2022)	96,4	84,4	99,1
Powell (22.08.2022)	75,5	65,6	82,5
Powell (22.08.2022)	65,9	55,2	74,1
Powell (22.08.2022)	64,3	52,4	73,3
Powell (22.08.2022)	53,4	32,7	67,7
Powell (22.08.2022)	33,6	14,6	48,3
14-90 days post exposure			
Powell (22.08.2022)	91,2	80,0	96,1
Powell (22.08.2022)	86,5	85,1	87,8
Powell (22.08.2022)	85,5	84,0	86,9
Powell (22.08.2022)	84,7	82,6	86,5
Powell (22.08.2022)	83,5	82,5	84,5
Amir (25.05.2022)	80,8	76,7	83,1
Cocchio (20.08.2022)	72,0	70,0	73,0
Cocchio (20.08.2022)	71,0	66,0	74,0
Powell (22.08.2022)	62,9	60,5	65,1
Chiew (28.09.2022)	40,0	34,0	45,0
Cocchio (20.08.2022)	32,0	26,0	38,0
Cocchio (20.08.2022)	30,0	27,0	33,0
<14 days post exposure			
Powell (22.08.2022)	95,5	85,3	98,6
Powell (22.08.2022)	87,4	83,5	90,4
Powell (22.08.2022)	86,1	82,3	89,1
Powell (22.08.2022)	84,9	81,3	87,8
Powell (22.08.2022)	82,1	80,1	83,9
Cocchio (20.08.2022)	82,0	77,0	86,0
Cocchio (20.08.2022)	80,0	75,0	84,0
Cocchio (20.08.2022)	80,0	78,0	82,0
Cocchio (20.08.2022)	79,0	77,0	88,0
Chiew (28.09.2022)	59,0	56,0	62,0
Buchan (07.04.2022)	56,0	34,0	70,0
Powell (22.08.2022)	55,1	50,7	59,1
No information			
Carazo (03.05.2022)	79,0	74,0	93,0
Ionescu (28.06.2022)	65,7	41,9	79,8
Ionescu (28.06.2022)	63,3	47,2	74,6
Buchan (07.04.2022)	62,0	49,0	72,0
Chiew (28.09.2022)	56,0	53,0	58,0
Cocchio (20.08.2022)	53,0	50,0	56,0
Cocchio (20.08.2022)	38,0	36,0	40,0

SF14: Infection: Children and adolescents (5-17 years), Exposure 3, Reference less exposures (2 exposures) (n=1)




Author (date)	VE in %	lower CI 95%	upper CI 95%
14-90 days post exposure			
Amir (25.05.2022)	76,2	72,2	79,6


SF15: Infection: Children and adolescents (5-17 years), Exposure 1-3, Reference unvaccinated (n=17)

Author (Date)	VE in %	lower CI 95%	upper CI 95%	Fowlkes (11.03.2022)	59,0	22,0	79,0
>180 days post exposure							
Powell (22.08.2022)	90,2	75,9	96,0	Coccio (20.08.2022)	59,0	55,0	62,0
Powell (22.08.2022)	77,2	67,5	84,0	Amir (25.05.2022)	58,3	54,6	61,5
Powell (22.08.2022)	67,8	24,1	86,3	Florentino (08.08.2022)	58,0	52,9	62,6
Powell (22.08.2022)	66,7	35,2	82,9	Ionescu (28.06.2022)	57,7	37,2	71,6
Powell (22.08.2022)	55,8	17,2	76,4	Coccio (20.08.2022)	55,0	49,0	61,0
Buchan (07.04.2022)	29,0	17,0	38,0	Veneti (25.03.2022)	53,1	42,6	61,7
Powell (22.08.2022)	25,7	-4,2	47,0	Florentino (08.08.2022)	53,0	51,3	54,7
Powell (22.08.2022)	19,4	11,7	26,4	Coccio (20.08.2022)	53,0	51,0	55,0
Powell (22.08.2022)	14,7	-63,3	55,4	Chemaitley (26.07.2022)	51,3	34,9	63,6
Powell (22.08.2022)	12,8	-1,6	25,1	Powell (22.08.2022)	51,2	28,4	66,8
Nordstrom (24.10.2022)	4,0	2,0	6,0	Cohen-Stavi (29.06.2022)	51,0	39,0	61,0
Chemaitley (26.07.2022)	-1,7	-20,0	10,0	Buchan (07.04.2022)	51,0	38,0	61,0
91-180 days post exposure							
Powell (22.08.2022)	85,5	77,5	90,6	Chemaitley (26.07.2022)	49,6	28,5	64,5
Powell (22.08.2022)	76,2	63,7	70,3	Ionescu (28.06.2022)	48,1	39,9	55,1
Powell (22.08.2022)	74,4	67,2	78,4	Cohen-Stavi (29.06.2022)	48,0	29,0	63,0
Powell (22.08.2022)	69,5	64,5	73,8	Nordstrom (24.10.2022)	47,0	43,0	51,0
Powell (22.08.2022)	65,9	60,5	70,6	Veneti (25.03.2022)	45,7	34,8	54,7
Fowlkes (11.03.2022)	62,0	-28,0	89,0	Florentino (08.08.2022)	45,3	37,2	52,4
Powell (22.08.2022)	59,3	46,7	69,0	Rudan (28.09.2022)	43,4	26,9	56,2
Carazo (03.05.2022)	57,0	36,0	71,0	Rudan (28.09.2022)	43,3	30,0	54,2
Powell (22.08.2022)	52,4	50,9	53,8	Ionescu (28.06.2022)	40,8	23,2	54,4
Ionescu (28.06.2022)	50,9	44,9	56,3	Florentino (08.08.2022)	40,6	38,8	42,4
Florentino (08.08.2022)	50,6	42,7	57,4	Tan (20.07.2022)	37,6	35,7	39,3
Rudan (28.09.2022)	48,7	22,0	66,3	Tsang (25.08.2022)	32,4	-29,0	64,6
Ionescu (28.06.2022)	47,5	37,6	55,8	Florentino (08.08.2022)	32,0	30,0	33,9
Ionescu (28.06.2022)	46,0	40,9	50,7	Fowlkes (11.03.2022)	31,0	9,0	48,0
Ionescu (28.06.2022)	44,6	40,0	49,0	Buchan (07.04.2022)	31,0	20,0	41,0
Ionescu (28.06.2022)	37,7	22,7	49,7	Rudan (28.09.2022)	30,2	18,4	40,3
Powell (22.08.2022)	36,6	32,9	40,1	Coccio (20.08.2022)	29,0	23,0	35,0
Nordstrom (24.10.2022)	36,0	34,0	23,0	Tan (20.07.2022)	28,5	26,3	30,7
Piche-Renaud (01.08.2022)	35,0	21,0	46,0	Florentino (08.08.2022)	25,3	22,9	27,6
Ionescu (28.06.2022)	33,9	24,1	42,4	Piche-Renaud (01.08.2022)	23,0	7,0	36,0
Ionescu (28.06.2022)	33,9	27,4	39,9	Coccio (20.08.2022)	23,0	19,0	27,0
Powell (22.08.2022)	32,7	27,7	37,4	Rudan (28.09.2022)	22,8	-6,4	44,0
Powell (22.08.2022)	29,8	24,9	34,2	Coccio (20.08.2022)	22,0	19,0	24,0
Buchan (07.04.2022)	29,0	19,0	38,0	Rudan (28.09.2022)	21,8	11,5	30,8
Tan (20.07.2022)	25,6	19,3	31,5	Veneti (25.03.2022)	21,2	-5,1	53,8
Veneti (25.03.2022)	23,3	2,7	39,5	Powell (22.08.2022)	18,8	17,2	20,3
Coccio (20.08.2022)	23,0	20,0	26,0	Cohen-Stavi (29.06.2022)	18,0	-2,0	34,0
Ionescu (28.06.2022)	22,2	8,4	33,9	Cohen-Stavi (29.06.2022)	17,0	7,0	25,0
Nordstrom (24.10.2022)	21,0	19,0	23,0	Florentino (08.08.2022)	17,0	13,8	20,0
Coccio (20.08.2022)	20,0	15,0	24,0	Rudan (28.09.2022)	16,9	8,7	24,4
Powell (22.08.2022)	17,9	14,9	20,7	Veneti (25.03.2022)	16,2	-2,4	31,3
Nordstrom (24.10.2022)	10,0	8,0	12,0	Veneti (25.03.2022)	15,1	-56,0	53,8
Rudan (28.09.2022)	9,5	-3,6	20,9	Rudan (28.09.2022)	11,9	-16,1	33,1
Coccio (20.08.2022)	8,0	5,0	11,0	Rudan (28.09.2022)	19,1	8,9	30,3
Florentino (08.08.2022)	5,9	2,2	9,4	Tsang (25.08.2022)	3,2	-220,7	70,8
Rudan (28.09.2022)	5,4	-13,4	21,0	Veneti (25.03.2022)	-1,3	-22,4	16,2
Piche-Renaud (01.08.2022)	4,0	-12,0	18,0	Veneti (25.03.2022)	-16,8	-87,3	27,1
Rudan (28.09.2022)	1,2	-49,3	34,6	Rudan (28.09.2022)	-22,4	-52,3	1,6
Veneti (25.03.2022)	-5,3	-32,9	16,6	Veneti (25.03.2022)	-33,7	-88,3	5,1
Chemaitley (26.07.2022)	-9,5	-30,0	35,0	<14 days post exposure			
Veneti (25.03.2022)	-12,8	-21,7	-4,6	Coccio (20.08.2022)	88,0	81,0	92,0
Rudan (28.09.2022)	-24,2	-46,5	-5,3	Coccio (20.08.2022)	83,0	79,0	86,0
Rudan (28.09.2022)	-24,7	-46,7	-6,0	Coccio (20.08.2022)	81,0	76,0	85,0
14-90 days post exposure				Powell (22.08.2022)	79,3	76,7	81,6
Powell (22.08.2022)	85,3	83,7	86,8	Coccio (20.08.2022)	78,0	69,0	84,0
Florentino (08.08.2022)	82,6	80,6	84,5	Powell (22.08.2022)	77,6	69,5	83,6
Powell (22.08.2022)	81,5	80,0	82,9	Coccio (20.08.2022)	72,0	69,0	74,0
Rudan (28.09.2022)	81,2	77,7	84,2	Coccio (20.08.2022)	70,0	67,0	72,0
Powell (22.08.2022)	79,6	44,9	92,4	Powell (22.08.2022)	69,2	55,9	78,5
Powell (22.08.2022)	78,8	77,9	79,5	Florentino (08.08.2022)	61,0	56,9	64,8
Florentino (08.08.2022)	77,4	74,7	79,8	Florentino (08.08.2022)	58,7	56,4	61,0
Ionescu (28.06.2022)	75,6	65,8	82,6	Powell (22.08.2022)	52,2	50,4	53,9
Florentino (08.08.2022)	69,6	66,3	72,6	Tan (20.07.2022)	48,8	46,9	50,8
Rudan (28.09.2022)	68,5	63,4	72,9	Rudan (28.09.2022)	46,9	37,0	55,3
Piche-Renaud (01.08.2022)	67,0	60,0	72,0	Florentino (08.08.2022)	42,5	29,4	53,3
Rudan (28.09.2022)	65,5	56,0	73,0	Florentino (08.08.2022)	37,5	28,5	45,3
Florentino (08.08.2022)	65,4	61,9	68,7	Rudan (28.09.2022)	34,0	13,2	49,9
Florentino (08.08.2022)	64,7	63,0	66,3	Florentino (08.08.2022)	19,7	10,6	27,9
Powell (22.08.2022)	64,5	63,6	65,4	Powell (22.08.2022)	15,2	9,9	20,1
Ionescu (28.06.2022)	63,4	21,4	83,0	Rudan (28.09.2022)	14,2	-10,3	33,1
Ionescu (28.06.2022)	59,3	50,9	66,3	Florentino (08.08.2022)	10,1	-14,2	29,1
No information				Veneti (25.03.2022)	9,5	-55,2	47,3
				Rudan (28.09.2022)	-18,4	-89,3	26,0

Carazo (03.05.2022)	78,0	70,0	83,0	Chemaitlely (26.07.2022)	25,7	10,0	38,6
Tan (20.07.2022)	65,3	62,0	68,3	Florentino (08.08.2022)	25,1	21,3	28,7
Fowlkes (11.03.2022)	59,0	24,0	78,0	Chiew (28.09.2022)	25,0	21,0	29,0
Ionescu (28.06.2022)	55,2	49,5	60,3	Tan (20.07.2022)	24,3	19,5	28,9
Piche-Renaud (01.08.2022)	54,0	48,0	59,0	Chiew (28.09.2022)	22,0	13,0	31,0
Ionescu (28.06.2022)	41,9	37,7	45,8	Cocchio (20.08.2022)	17,0	15,0	20,0
Cocchio (20.08.2022)	35,0	34,0	37,0	Piche-Renaud (01.08.2022)	13,0	3,0	21,0
Ionescu (28.06.2022)	33,9	25,7	41,1	Nordstrom (24.10.2022)	-2,0	-4,0	0,0
Chemaitlely (26.07.2022)	30,6	26,9	34,1				
Cocchio (20.08.2022)	30,0	26,0	33,0				
Florentino (08.08.2022)	28,0	26,3	29,7				




SF16: Severe disease: General population (adults 18+ years), Exposure 3+, Reference unvaccinated (n=10)



Author (Date)	VE in %	lower CI 95%	upper CI 95%
91-180 days post exposure			
Grewal (01.11.2022)	86,0	44,0	96,0
Lin (26.09.2022)	40,7	9,0	61,3
Lin (26.09.2022)	37,3	0,0	64,2
14-90 days post exposure			
Šmíd (25.02.2022)	98,0	95,0	98,0
Grewal (01.11.2022)	97,0	91,0	99,0
Šmíd (25.02.2022)	97,0	87,0	99,0
Grewal (01.11.2022)	93,0	72,0	98,0
Ferdinands (03.10.2022)	76,0	71,0	80,0
Šmíd (25.02.2022)	72,0	0,0	96,0
Ferdinands (03.10.2022)	70,0	56,0	79,0
Surie (21.10.2022)	61,0	37,0	76,0
Surie (21.10.2022)	61,0	29,0	78,0
Lin (26.09.2022)	49,7	16,2	69,8
Lin (26.09.2022)	46,8	21,1	64,2
Lin (26.09.2022)	43,8	19,4	60,9
No information			
Altarawneh (15.06.2022)	100,0	91,8	100,0
Carazo (03.05.2022)	97,0	94,0	99,0
Castillo (21.04.2022)	84,0	72,0	95,0
Link-Gelles (15.07.2022)	80,0	71,0	85,0
Castillo (21.04.2022)	71,0	64,0	78,0
Plumb (12.04.2022)	67,6	61,4	72,8


SF17: Severe disease: General population (adults 18+ years), Exposure 3, Reference unvaccinated (n=24)

Author (Date)	VE in %	lower CI 95%	upper CI 95%	Hansen (30.03.2022)	88,5	87,4	89,6
>180 days post exposure							
Grewal (01.11.2022)	88,0	83,0	92,0	Hansen (30.03.2022)	87,8	84,5	90,4
Grewal (01.11.2022)	87,0	81,0	92,0	Šmíd (25.02.2022)	87,7	85,3	89,7
Tartof (30.06.2022)	65,0	56,0	73,0	Castillo (21.04.2022)	87,0	80,0	93,0
Ferdinands (03.10.2022)	41,0	35,0	47,0	Ferdinands (03.10.2022)	86,0	85,0	87,0
Ferdinands (03.10.2022)	31,0	17,0	43,0	Šmíd (25.02.2022)	85,0	80,0	88,0
91-180 days post exposure							
Castillo (21.04.2022)	95,0	91,0	99,0	Tartof (22.04.2022)	85,0	80,0	89,0
Grewal (01.11.2022)	94,0	91,0	96,0	Hansen (30.03.2022)	84,9	83,1	86,5
Link-Gelles (15.07.2022)	94,0	62,0	99,0	Castillo (21.04.2022)	84,0	82,0	87,0
Castillo (21.04.2022)	86,0	84,0	89,0	Šmíd (25.02.2022)	83,0	75,0	89,0
Hansen (30.03.2022)	83,6	77,7	88,0	Lin (26.09.2022)	82,7	77,6	86,7
Cerqueira-Silva (14.04.2022)	80,2	78,0	82,2	Castillo (21.04.2022)	82,0	79,0	85,0
Hansen (30.03.2022)	79,0	76,5	81,3	Castillo (21.04.2022)	82,0	78,0	86,0
Hansen (30.03.2022)	77,3	63,1	86,1	Chemaitlely (02.06.2022)	81,8	-49,5	97,8
Tartof (30.06.2022)	76,0	69,0	82,0	Cerqueira-Silva (14.04.2022)	81,8	69,1	89,3
Stowe (01.04.2022)	75,9	15,8	93,1	Lin (26.09.2022)	80,9	76,6	84,4
Cerqueira-Silva (14.04.2022)	75,8	55,0	87,0	Tartof (30.06.2022)	80,0	74,0	84,0
Tartof (30.06.2022)	70,0	53,0	81,0	Adams (14.06.2022)	80,0	74,0	84,0
Lin (26.09.2022)	69,4	63,1	74,6	Surie (21.10.2022)	79,0	74,0	84,0
Hansen (30.03.2022)	66,2	61,1	70,7	Šmíd (25.02.2022)	79,0	75,0	83,0
Ferdinands (03.10.2022)	66,0	63,0	68,0	Tartof (22.04.2022)	77,0	72,0	81,0
Adams (14.06.2022)	65,0	47,0	77,0	Tartof (30.06.2022)	74,0	47,0	87,0
Lin (26.09.2022)	61,2	55,3	66,2	Tartof (30.06.2022)	74,0	69,0	78,0
Tartof (22.04.2022)	53,0	36,0	66,0	Lin (26.09.2022)	73,3	68,0	77,7
Link-Gelles (15.07.2022)	52,0	44,0	59,0	Link-Gelles (15.07.2022)	69,0	58,0	76,0
Surie (21.10.2022)	41,0	23,0	55,0	Link-Gelles (05.10.2022)	68,0	50,0	80,0
Link-Gelles (05.10.2022)	41,0	23,0	55,0	Link-Gelles (05.10.2022)	62,0	54,0	66,0
Link-Gelles (05.10.2022)	36,0	29,0	42,0	Surie (21.10.2022)	60,0	12,0	81,0
Chatzilena (12.09.2022)	33,9	8,4	52,4	Šmíd (25.02.2022)	60,0	37,0	74,0
Link-Gelles (05.10.2022)	32,0	29,0	36,0	Tartof (30.06.2022)	59,0	40,0	72,0
Surie (21.10.2022)	29,0	3,0	48,0	Chatzilena (12.09.2022)	31,0	-15,3	59,1
<14 days post exposure							
Grewal (01.11.2022)	96,0			Grewal (01.11.2022)	96,0	91,0	98,0
Buchan (22.09.2022)	91,0			Buchan (22.09.2022)	91,0	71,0	97,0
Stowe (01.04.2022)	90,7			Stowe (01.04.2022)	90,7	56,0	98,1
Castillo (21.04.2022)	88,0			Castillo (21.04.2022)	88,0	79,0	98,0
Castillo (21.04.2022)	88,0			Castillo (21.04.2022)	88,0	78,0	98,0
Castillo (21.04.2022)	72,0			Castillo (21.04.2022)	72,0	64,0	79,0
Castillo (21.04.2022)	65,0			Castillo (21.04.2022)	65,0	57,0	73,0
No information							
Tseng (21.04.2022)	99,2			Tseng (21.04.2022)	99,2	76,3	100,0
Tseng (01.10.2022)	97,5			Tseng (01.10.2022)	97,5	96,3	98,3
Altarawneh (15.06.2022)	94,3			Altarawneh (15.06.2022)	94,3	81,3	98,3
Carazo (03.05.2022)	94,0			Carazo (03.05.2022)	94,0	91,0	96,0
Altarawneh (15.06.2022)	92,5			Altarawneh (15.06.2022)	92,5	84,4	96,3
Carazo (03.05.2022)	91,0			Carazo (03.05.2022)	91,0	91,0	92,0
Young-Xu (03.08.2022)	89,0			Young-Xu (03.08.2022)	89,0	88,0	91,0
Tseng (01.10.2022)	82,0			Tseng (01.10.2022)	82,0	64,5	90,8
Adams (14.06.2022)	77,0			Adams (14.06.2022)	77,0	71,0	82,0
Yan (18.08.2022)	75,5			Yan (18.08.2022)	75,5	38,9	90,2
Tseng (01.10.2022)	72,4			Tseng (01.10.2022)	72,4	23,9	90,0
Plumb (12.04.2022)	34,6			Plumb (12.04.2022)	34,6	25,5	42,5
Chatzilena (12.09.2022)	30,9			Chatzilena (12.09.2022)	30,9	5,9	49,3




SF18: Severe disease: General population (adults 18+), Exposure 3, Reference less exposures (2 exposures) (n=9)

Author (date)	VE in %	lower CI 95%	upper CI 95%
>180 days post exposure			
Ng (26.08.2022)	89,0	78,9	94,2
Ng (26.08.2022)	87,3	84,2	89,8
Ng (26.08.2022)	86,3	44,7	96,6
Ng (26.08.2022)	84,4	73,4	90,9
91-180 days post exposure			
Butt (03.05.2022)	83,0	24,0	96,0
Chemaitlely (15.11.2022)	80,5	55,7	91,4
Chemaitlely (15.11.2022)	79,9	54,2	91,2
Butt (03.05.2022)	79,0	-78,0	98,0
Chemaitlely (15.11.2022)	52,8	-61,2	91,4
Butt (03.05.2022)	45,0	18,0	63,0
14-90 days post exposure			
Ng (26.08.2022)	97,5	89,7	99,4
Andersson (29.11.2022)	96,8	92,6	100
Andersson (29.11.2022)	94,4	85,5	100
Ng (26.08.2022)	93,8	88,2	96,8
Butt (03.05.2022)	90,0	22,0	99,0
Andersson (29.11.2022)	88,7	84,2	93,2
Ng (26.08.2022)	88,0	77,8	93,6
Ng (26.08.2022)	87,3	72,8	94,1
Ng (26.08.2022)	87,0	70,4	94,3
Butt (03.05.2022)	87,0	41,0	97,0
Gonzales (27.09.2022)	86,0	23,0	97,0
Butt (03.05.2022)	86,0	-17,0	98,0
Ng (26.08.2022)	85,2	80,2	88,9
Andersson (29.11.2022)	83,7	79,0	88,4
Ng (26.08.2022)	81,0	76,3	84,7
Andersson (29.11.2022)	80,1	70,8	89,3
Gonzales (27.09.2022)	78,0	65,0	86,0
Andersson (29.11.2022)	77,9	65,2	90,6
Andersson (29.11.2022)	76,5	36,5	100
Andersson (29.11.2022)	76,3	59,9	93,1
Butt (03.05.2022)	63,0	45,0	74,0
Butt (03.05.2022)	62,0	43,0	75,0
Butt (03.05.2022)	58,0	46,0	67,0
Butt (03.05.2022)	55,0	38,0	67,0
Butt (03.05.2022)	50,0	-68,0	85,0
Butt (03.05.2022)	47,0	20,0	65,0
Butt (03.05.2022)	44,0	31,0	55,0
No information			
Tseng (01.10.2022)	88,8	83,3	92,5
Liu (21.06.2022)	87,8	77,3	93,4
Tseng (01.10.2022)	87,5	51,8	96,8
Butt (03.05.2022)	83,0	65,0	92,0
Abu-Raddad (12.05.2022)	76,5	55,9	87,5
Tseng (01.10.2022)	75,0	47,6	88,1
Liu (21.06.2022)	65,2	60,8	69,1
Ioannou (16.06.2022)	63,2	56,4	69,0
Ioannou (16.06.2022)	54,0	46,1	60,8
Ioannou (16.06.2022)	53,7	45,8	60,4
Ioannou (16.06.2022)	53,3	43,2	61,6
Ioannou (16.06.2022)	53,3	48,1	58,0
Ioannou (16.06.2022)	53,1	45,7	59,5
Liu (21.06.2022)	52,9	36,9	64,8
Ioannou (16.06.2022)	52,9	45,6	59,2
Butt (03.05.2022)	52,0	46,0	57,0
Liu (21.06.2022)	49,4	30,8	63,0
Ioannou (16.06.2022)	43,8	35,2	51,3




SF19: Severe disease: General population (adults 18+ years), Exposure 1-3, Reference unvaccinated (n=23)

Author (Date)	VE in %	lower CI 95%	upper CI 95%				
>180 days post exposure							
Šmíd (25.02.2022)	92,0	86,0	96,0	Surie (21.10.2022)	83,0	35,0	96,0
Šmíd (25.02.2022)	88,0	72,0	94,0	Grewal (01.11.2022)	79,0	60,0	89,0
Grewal (01.11.2022)	86,0	82,0	89,0	Gram (01.09.2022)	79,0	57,5	89,6
Stowe (01.04.2022)	82,3	67,7	90,3	Castillo (21.04.2022)	78,0	57,0	100,0
Grewal (01.11.2022)	82,0	75,0	87,0	Grewal (01.11.2022)	77,0	65,0	84,0
Buchan (22.09.2022)	82,0	62,0	91,0	Stowe (01.04.2022)	75,0	42,4	89,1
Grewal (01.11.2022)	77,0	69,0	83,0	Ferdinands (03.10.2022)	73,0	63,0	80,0
Castillo (21.04.2022)	68,0	58,0	79,0	Link-Gelles (15.07.2022)	71,0	65,0	75,0
Šmíd (25.02.2022)	66,0	15,0	86,0	Gram (01.09.2022)	70,5	40,3	85,5
Tartof (30.06.2022)	56,0	28,0	73,0	Chemaitlely (02.06.2022)	70,4	45,0	84,0
Ferdinands (03.10.2022)	55,0	51,0	58,0	Ferdinands (03.10.2022)	68,0	59,0	75,0
Ferdinands (03.10.2022)	51,0	47,0	54,0	Tartof (22.04.2022)	68,0	48,0	80,0
Tartof (22.04.2022)	51,0	43,0	59,0	Castillo (21.04.2022)	68,0	41,0	94,0
Castillo (21.04.2022)	50,0	44,0	57,0	Tartof (22.04.2022)	64,0	51,0	73,0
Ferdinands (03.10.2022)	48,0	42,0	53,0	Link-Gelles (15.07.2022)	64,0	52,0	73,0
Tartof (22.04.2022)	41,0	21,0	55,0	Surie (21.10.2022)	63,0	46,0	75,0
Ferdinands (03.10.2022)	40,0	32,0	47,0	Ferdinands (03.10.2022)	61,0	54,0	67,0
Surie (21.10.2022)	37,0	12,0	55,0	Castillo (21.04.2022)	60,0	47,0	73,0
Surie (21.10.2022)	34,0	20,0	46,0	Šmíd (25.02.2022)	59,0	3,0	82,0
Tartof (30.06.2022)	32,0	16,0	45,0	Šmíd (25.02.2022)	57,0	32,0	72,0
Tartof (22.04.2022)	31,0	16,0	43,0	Link-Gelles (15.07.2022)	57,0	19,0	77,0
Ferdinands (03.10.2022)	19,0	6,0	30,0	Tartof (30.06.2022)	56,0	-2,0	81,0
Tartof (30.06.2022)	19,0	6,0	31,0	Tartof (30.06.2022)	54,0	38,0	65,0
Tartof (30.06.2022)	12,0	-10,0	31,0	Adams (14.06.2022)	54,0	32,0	69,0
91-180 days post exposure							
Chemaitlely (07.07.2022)	88,6	70,9	95,5	Hansen (30.03.2022)	50,5	33,9	63,0
Šmíd (25.02.2022)	87,0	73,0	94,0	Hansen (30.03.2022)	48,5	36,6	58,2
Gram (01.09.2022)	85,8	73,8	92,3	Link-Gelles (05.10.2022)	47,0	33,0	58,0
Grewal (01.11.2022)	85,0	79,0	89,0	Castillo (21.04.2022)	46,0	-2,0	94,0
Castillo (21.04.2022)	85,0	76,0	93,0	Šmíd (25.02.2022)	45,0	29,0	54,0
Šmíd (25.02.2022)	83,0	0,0	98,0	Castillo (21.04.2022)	44,0	29,0	59,0
Šmíd (25.02.2022)	81,0	40,0	94,0	Hansen (30.03.2022)	42,6	26,9	54,9
Castillo (21.04.2022)	81,0	72,0	89,0	Tartof (30.06.2022)	42,0	31,0	52,0
Carazo (03.05.2022)	81,0	66,0	89,0	Šmíd (25.02.2022)	37,0	12,0	55,0
Gram (01.09.2022)	77,6	72,6	81,6	Šmíd (25.02.2022)	32,0	20,0	43,0
Chemaitlely (02.06.2022)	77,5	67,8	84,3	Šmíd (25.02.2022)	29,0	21,0	37,0
Buchan (22.09.2022)	75,0	51,0	87,0	Castillo (21.04.2022)	28,0	5,0	50,0
Castillo (21.04.2022)	75,0	58,0	91,0	Tartof (30.06.2022)	27,0	-11,0	52,0
Altarawneh (15.06.2022)	71,6	15,7	90,4	Castillo (21.04.2022)	1,0	-23,0	25,0
Castillo (21.04.2022)	70,0	65,0	76,0	Castillo (21.04.2022)	-9,0	-69,0	51,0
Chemaitlely (02.06.2022)	68,4	46,1	81,5	No information			
Castillo (21.04.2022)	57,0	51,0	64,0	Carazo (03.05.2022)	86,0	77,0	91,0
Ferdinands (03.10.2022)	57,0	51,0	62,0	Tseng (21.04.2022)	84,5	23,0	96,9
Link-Gelles (15.07.2022)	52,0	43,0	59,0	Yan (18.08.2022)	80,4	40,7	93,5
Hansen (30.03.2022)	51,6	47,2	55,6	Yan (18.08.2022)	78,3	60,8	88,0
Hansen (30.03.2022)	47,2	33,7	57,9	Carazo (03.05.2022)	76,0	74,0	78,0
Castillo (21.04.2022)	42,0	32,0	52,0	Altarawneh (15.06.2022)	73,5	60,5	82,2
Adams (14.06.2022)	42,0	28,0	54,0	Risk (16.08.2022)	68,0	53,0	78,0
Link-Gelles (05.10.2022)	33,0	15,0	48,0	Young-Xu (03.08.2022)	63,0	58,0	67,0
Link-Gelles (05.10.2022)	28,0	24,0	31,0	Castillo (21.04.2022)	58,0	28,0	88,0
Link-Gelles (05.10.2022)	25,0	12,0	32,0	Ferdinands (03.10.2022)	58,0	53,0	62,0
Link-Gelles (15.07.2022)	24,0	12,0	35,0	Castillo (21.04.2022)	55,0	40,0	70,0
14-90 days post exposure							
Gram (01.09.2022)	96,2	72,9	99,5	Carazo (03.05.2022)	52,0	42,0	61,0
Chemaitlely (02.06.2022)	87,1	40,2	97,2	Castillo (21.04.2022)	49,0	34,0	64,0
Stowe (01.04.2022)	86,7	63,6	95,1	Adams (14.06.2022)	47,0	30,0	60,0
				Adams (14.06.2022)	46,0	30,0	58,0
				Adams (14.06.2022)	44,0	31,0	54,0
				Adams (14.06.2022)	41,0	9,0	62,0
				Chemaitlely (02.06.2022)	40,9	-199,1	88,3
				Plumb (12.04.2022)	33,0	15,0	47,2




-100 -90 -80 -70 -60 -50 -40 -30 -20 -10 0 10 20 30 40 50 60 70 80 90 100

SF20: Severe disease: Older adults (60+ years), Exposure 3+, Reference unvaccinated (n=4)




SF21: Severe disease: Older adults (60+ years), Exposure 3+, Reference less exposures (3 exposures) (n=10)




SF22: Severe disease: Older adults (60+ years), Exposure 3, Reference unvaccinated (n=12)

Author (Date)	VE in %	lower CI 95%	upper CI 95%
>180 days post exposure			
Grewal (01.11.2022)	85,0	78,0	90,0
Grewal (01.11.2022)	82,0	77,0	87,0
Grewal (01.11.2022)	79,0	71,0	85,0
Grewal (01.11.2022)	79,0	73,0	84,0
Grewal (01.11.2022)	76,0	68,0	82,0
Grewal (01.11.2022)	75,0	68,0	80,0
91-180 days post exposure			
Grewal (01.11.2022)	91,0	88,0	93,0
Grewal (01.11.2022)	89,0	86,0	91,0
Stowe (01.04.2022)	86,8	77,1	92,3
Grewal (01.11.2022)	82,0	79,0	86,0
Grewal (08.06.2022)	77,0	69,0	82,0
Grewal (30.09.2022)	72,0	64,0	78,0
Chatzilena (12.09.2022)	46,9	16,3	66,4
Link-Gelles (05.10.2022)	46,0	28,0	60,0
Link-Gelles (05.10.2022)	38,0	30,0	46,0
Link-Gelles (05.10.2022)	38,0	32,0	43,0
14-90 days post exposure			
Grewal (01.11.2022)	98,0	97,0	98,0
Baum (06.07.2022)	98,0	95,0	99,0
Grewal (01.11.2022)	96,0	95,0	97,0
Stowe (01.04.2022)	95,8	91,3	97,9
Baum (06.07.2022)	95,0	94,0	96,0
Grewal (01.11.2022)	94,0	92,0	95,0
Stowe (01.04.2022)	92,8	88,4	95,6
Stowe (01.04.2022)	92,5	88,1	95,2
Grewal (01.11.2022)	92,0	90,0	94,0
Wan (17.10.2022)	92,0	89,5	93,9
Wan (17.10.2022)	91,4	90,1	92,5
Grewal (01.11.2022)	91,0	89,0	92,0
Wan (17.10.2022)	90,4	82,9	94,6
Wan (17.10.2022)	86,4	62,8	95,1
Grewal (01.11.2022)	86,0	84,0	89,0
Grewal (08.06.2022)	80,0	72,0	86,0
Grewal (30.09.2022)	77,0	68,0	83,0
Link-Gelles (05.10.2022)	73,0	55,0	84,0
Link-Gelles (05.10.2022)	56,0	39,0	68,0
Chatzilena (12.09.2022)	50,8	-12,2	79,2
<14 days post exposure			
Grewal (01.11.2022)	95,0	91,0	97,0
Stowe (01.04.2022)	94,7	71,6	99,0
Stowe (01.04.2022)	89,2	63,1	96,8
Grewal (01.11.2022)	88,0	81,0	92,0
Grewal (01.11.2022)	66,0	48,0	77,0
No information			
Kirsbom (01.05.2022)	90,9	88,7	92,7
Yan (18.08.2022)	90,8	83,4	94,9
Sharma (27.04.2022)	87,9	85,3	90,2
Kirsbom (01.05.2022)	82,3	64,2	91,3
Sharma (27.04.2022)	81,8	79,2	84,2
Kislaya (15.09.2022)	74,0	66,0	80,0
Kislaya (15.09.2022)	63,0	55,0	70,0
Chatzilena (12.09.2022)	47,2	16,8	66,6




SF23: Severe disease: Older adults (60+ years), Exposure 3, Reference less exposures (2 exposures) (n=4)




Author (date)	VE in %	lower CI 95%	upper CI 95%
>180 days post exposure			
Amir (05.05.2022)	68,1	62,8	72,6
91-180 days post exposure			
Amir (05.05.2022)	66,4	63,6	69,8
Amir (05.05.2022)	64,7	64,2	65,1
Amir (05.05.2022)	64,7	64,3	65,1
14-90 days post exposure			
Amir (05.05.2022)	68,1	58,9	75,5
Amir (05.05.2022)	66,4	51,2	76,4
Amir (05.05.2022)	56,9	44,2	67,0
No information			
Sharma (27.04.2022)	63,5	53,7	71,6
Sharma (27.04.2022)	61,4	55,0	67,1
Ioannou (16.06.2022)	54,2	45,4	61,6
Ioannou (16.06.2022)	52,3	42,1	60,7
Kislaya (15.09.2022)	21,0	2,0	36,0
Kislaya (15.09.2022)	16,0	1,0	28,0

SF24: Severe disease: Older adults (60+ years), Exposure 1-3, Reference unvaccinated (n=11)

Author (Date)	VE in %	lower CI 95%	upper CI 95%
>180 days post exposure			
Grewal (01.11.2022)	84,0	80,0	87,0
Grewal (01.11.2022)	75,0	67,0	80,0
Stowe (01.04.2022)	73,4	55,1	84,3
Grewal (01.11.2022)	72,0	64,0	78,0
Grewal (01.11.2022)	71,0	63,0	78,0
Grewal (01.11.2022)	70,0	62,0	77,0
Grewal (01.11.2022)	69,0	62,0	75,0
Grewal (01.11.2022)	68,0	59,0	75,0
Grewal (01.11.2022)	64,0	55,0	71,0
Kirsbom (01.05.2022)	61,0	49,8	69,7
Grewal (01.11.2022)	46,0	34,0	56,0
91-180 days post exposure			
Baum (06.07.2022)	92,0	87,0	95,0
Baum (06.07.2022)	85,0	82,0	87,0
Grewal (01.11.2022)	79,0	73,0	84,0
Grewal (01.11.2022)	76,0	67,0	82,0
Baum (06.07.2022)	74,0	60,0	83,0
Grewal (01.11.2022)	60,0	47,0	70,0
Link-Gelles (05.10.2022)	44,0	23,0	59,0
Link-Gelles (05.10.2022)	31,0	21,0	39,0
Link-Gelles (05.10.2022)	31,0	24,0	37,0
14-90 days post exposure			
Baum (06.07.2022)	98,0	95,0	99,0
Baum (06.07.2022)	93,0	89,0	95,0
Stowe (01.04.2022)	90,9	72,6	97,0
Wan (17.10.2022)	87,1	72,3	94,0
Grewal (01.11.2022)	86,0	78,0	92,0
Grewal (01.11.2022)	84,0	61,0	93,0
Grewal (01.11.2022)	84,0	57,0	94,0
Wan (17.10.2022)	82,0	79,6	84,2
Grewal (01.11.2022)	81,0	69,0	88,0
Grewal (01.11.2022)	80,0	62,0	90,0
Wan (17.10.2022)	78,3	67,6	85,5
Stowe (01.04.2022)	78,3	43,7	91,7
Link-Gelles (05.10.2022)	78,0	63,0	87,0
Wan (17.10.2022)	74,9	72,6	77,0
Wan (17.10.2022)	63,9	58,6	68,4
Grewal (01.11.2022)	57,0	27,0	75,0
Wan (17.10.2022)	50,5	13,7	71,6
Wan (17.10.2022)	44,8	14,8	64,3
Wan (17.10.2022)	44,8	38,4	50,5
No information			
Yan (18.08.2022)	82,1	74,6	87,3
Kislaya (15.09.2022)	67,0	56,0	75,0
Sharma (27.04.2022)	66,7	61,4	71,6
Kislaya (15.09.2022)	56,0	46,0	65,0
Sharma (27.04.2022)	52,9	47,8	57,6
Grewal (08.06.2022)	52,0	33,0	65,0
Grewal (30.09.2022)	43,0	24,0	58,0
Yan (18.08.2022)	39,1	13,0	57,4




SF25: Severe disease: Children and adolescents (5-17 years), Exposure 3, Reference vaccinated (n=4)




SF26: Severe disease: Children and adolescents (5-17 years), Exposure 1-3, Reference unvaccinated (n=11)

Author (Date)	VE in %	lower CI 95%	upper CI 95%
>180 days post exposure			
Buchan (07.04.2022)	88,0	77,0	94,0
Price (30.03.2022)	38,0	-3,0	62,0
Tartof (03.08.2022)	16,0	-7,0	34,0
91-180 days post exposure			
Zambrano (04.08.2022)	92,0	71,0	98,0
Florentino (08.08.2022)	82,7	68,8	90,4
Buchan (07.04.2022)	82,0	64,0	91,0
Tartof (03.08.2022)	45,0	28,0	57,0
Klein (01.03.2022)	-2,0	-25,0	17,0
Klein (01.03.2022)	-3,0	-30,0	18,0
14-90 days post exposure			
Piche-Renaud (01.08.2022)	94,0	56,0	99,0
Florentino (08.08.2022)	86,4	75,2	92,6
Nordstrom (24.10.2022)	86,0	63,0	95,9
Florentino (08.08.2022)	84,2	76,3	89,5
Florentino (08.08.2022)	83,7	76,0	88,9
Buchan (07.04.2022)	83,0	55,0	93,0
Florentino (08.08.2022)	82,8	72,1	89,4
Florentino (08.08.2022)	82,0	72,6	88,2
Zambrano (04.08.2022)	78,0	48,0	90,0
Buchan (07.04.2022)	76,0	-10,0	95,0
Florentino (08.08.2022)	75,6	58,1	85,8
Piche-Renaud (01.08.2022)	74,0	44,0	88,0
Tartof (03.08.2022)	73,0	54,0	84,0
Klein (01.03.2022)	51,0	30,0	65,0
Klein (01.03.2022)	45,0	30,0	57,0
Price (30.03.2022)	43,0	-1,0	68,0
Tartof (03.08.2022)	38,0	14,0	56,0
Klein (01.03.2022)	34,0	8,0	53,0
<14 days post exposure			
Florentino (08.08.2022)	65,0	37,2	80,5
Florentino (08.08.2022)	62,4	-22,2	88,5
Florentino (08.08.2022)	20,6	-152,2	75,0
No information			
Buchan (07.04.2022)	85,0	74,0	91,0
Tan (11.08.2022)	82,7	74,8	88,2
Piche-Renaud (01.08.2022)	81,0	64,0	90,0
Gonzalez (16.07.2022)	78,2	42,0	90,3
Nordstrom (24.10.2022)	75,0	54,0	86,0
Chiew (28.09.2022)	75,0	56,0	86,0
Price (30.03.2022)	68,0	42,0	82,0
Florentino (08.08.2022)	56,3	45,9	64,6
Tan (11.08.2022)	42,3	24,9	55,7
Chiew (28.09.2022)	33,0	0,0	76,0




SF27: Death: General population (adults 18+ years), Exposure 3+, Reference unvaccinated (n=1)




Author (Date)	VE in %	lower CI 95%	upper CI 95%
No information			
Castillo (21.04.2022)	81,0	68,0	94,0

SF28: Death: General population (adults 18+ years), Exposure 3, Reference unvaccinated (n=6)




Author (Date)	VE in %	lower CI 95%	upper CI 95%
>180 days post exposure			
Wang (25.03.2022)	77,0	69,0	83,0
91-180 days post exposure			
Castillo (21.04.2022)	87,0	83,0	92,0
14-90 days post exposure			
Lin (26.09.2022)	74,1	62,0	82,3
Lin (26.09.2022)	74,1	66,2	80,1
<14 days post exposure			
Castillo (21.04.2022)	87,7	80,9	92,1
Castillo (21.04.2022)	86,0	80,0	92,0
Castillo (21.04.2022)	85,0	60,0	94,0
Castillo (21.04.2022)	85,0	79,0	90,0
Castillo (21.04.2022)	82,0	72,0	92,0
Lin (26.09.2022)	80,0	73,6	84,9
Lin (26.09.2022)	77,8	71,8	82,5
No information			
Yan (18.08.2022)	98,4	95,0	99,5
Young-Xu (03.08.2022)	94,0	90,0	96,0
Jara (06.10.2022)	83,0	69,7	87,7
Yan (18.08.2022)	86,6	57,9	95,7

SF29: Death: General population (adults 18+ years), Exposure 3, Reference less exposures (2 exposures) (n=3)




Author (date)	VE in %	Lower CI 95%	Upper CI 95%
14-90 days post exposure			
Andersson (29.11.2022)	99,0	96,6	100
Andersson (29.11.2022)	96,8	92,6	100
Andersson (29.11.2022)	87,8	60,7	100
Andersson (29.11.2022)	80,9	69,5	92,4
Gonzales (27.09.2022)	80,0	68,0	87,0
Gonzales (27.09.2022)	75,0	-17,0	95,0
No information			
Ioannou (16.06.2022)	85,5	73,9	92,0
Ioannou (16.06.2022)	84,8	73,7	91,2
Ioannou (16.06.2022)	81,6	67,8	89,4
Ioannou (16.06.2022)	79,1	71,2	84,9
Ioannou (16.06.2022)	78,1	67,5	85,3
Ioannou (16.06.2022)	75,2	62,9	83,4
Ioannou (16.06.2022)	75,0	62,3	83,4

SF30: Death: General population (adults 18+ years), Exposure 1-3, Reference unvaccinated (n=4)




SF31: Death: Older adults (60+ years), Exposure 3+, Reference unvaccinated (n=1)




Author (Date)	VE in %	lower CI 95%	upper CI 95%
No information			
Kislaya (15.09.2022)	82,0	77,0	85,0
Kislaya (15.09.2022)	49,0	41,0	56,0

SF32: Death: Older adults (60+ years), Exposure 3+, Reference less exposures (3 exposures) (n=5)




Author (date)	VE in %	lower CI 95%	upper CI 95%
14-90 days post exposure			
Mc Coneghy (30.09.2022)	89,6	45,0	100,0
Magen (13.04.2022)	76,0	48,0	91,0
No information			
Arbel (25.04.2022)	78,0	72,0	83,0
Muhsen (23.06.2022)	76,0	58,0	87,0
Kislaya (15.09.2022)	56,0	47,0	63,0


SF33: Death: Older adults (60+ years), Exposure 3, Reference unvaccinated (n=4)




SF34: Death: Older adults (60+ years), Exposure 3, Reference less exposures (2 exposures) (n=3)



SF35: Death: Older adults (60+ years), Exposure 1-3, Reference unvaccinated (n=4)



SF36: Death: Children and adolescents (5-17 years), Exposure 1-3, Reference unvaccinated (n=1)



Literature

Included primary studies (n=90)

identified via:

International Vaccine Access Center, Johns Hopkins Bloomberg School of Public Health, World Health Organization, Coalition for Epidemic Preparedness Innovations. Results of COVID-19 Vaccine Effectiveness Studies: An Ongoing Systematic Review: Weekly Summary Tables. Updated December 1, 2022. Available from: URL: <https://view-hub.org/covid-19/effectiveness-studies>

1. Abu-Raddad, Laith J.; Chemaiteily, Hiam; Ayoub, Houssein H.; AlMukdad, Sawsan; Yassine, Hadi M.; Al-Khatib, Hebah A. et al. (2022): Effect of mRNA Vaccine Boosters against SARS-CoV-2 Omicron Infection in Qatar. In: N Engl J Med 386 (19), S. 1804–1816. DOI: 10.1056/NEJMoa2200797.
2. Adams, Katherine; Rhoads, Jillian P.; Surie, Diya; Gaglani, Manjusha; Ginde, Adit A.; McNeal, Tresa et al. (2022): Vaccine Effectiveness of Primary Series and Booster Doses against Omicron Variant COVID-19-Associated Hospitalization in the United States. In: medRxiv : the preprint server for health sciences. DOI: 10.1101/2022.06.09.22276228.
3. Altarawneh, Heba N.; Chemaiteily, Hiam; Ayoub, Houssein H.; Tang, Patrick; Hasan, Mohammad R.; Yassine, Hadi M. et al. (2022): Effects of Previous Infection and Vaccination on Symptomatic Omicron Infections. In: The New England journal of medicine 387 (1), S. 21–34. DOI: 10.1056/NEJMoa2203965.
4. Amir, Ofra; Goldberg, Yair; Mandel, Micha; Bar-On, Yinon M.; Bodenheimer, Omri; Freedman, Laurence et al. (2022): Protection against omicron severe disease 0-7 months after BNT162b2 booster. DOI: 10.1101/2022.05.04.22274647.
5. Amir, Ofra; Goldberg, Yair; Mandel, Micha; Bar-On, Yinon M.; Bodenheimer, Omri; Freedman, Laurence et al. (2022): Initial protection against Omicron in children and adolescents by BNT162b2. DOI: 10.1101/2022.05.22.22275323.
6. Andersson, Niklas Worm; Thiesson, Emilia Myrup; Baum, Ulrike; Pihlström, Nicklas; Starrfelt, Jostein; Faksová, Kristýna et al. (2022): Comparative effectiveness of heterologous booster schedules with AZD1222, BNT162b2, or mRNA-1273 vaccines against COVID-19 during omicron predominance in the Nordic countries. DOI: 10.1101/2022.11.24.22282651.
7. Arashiro, Takeshi; Arima, Yuzo; Muraoka, Hirokazu; Sato, Akihiro; Oba, Kunihiro; Uehara, Yuki et al. (2022): COVID-19 vaccine effectiveness against symptomatic SARS-CoV-2 infection during Delta-dominant and Omicron-dominant periods in Japan: a multi-center prospective case-control study (FASCINATE study). In: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. DOI: 10.1093/cid/ciac635.
8. Arbel, Ronen; Sergienko, Ruslan; Friger, Michael; Peretz, Alon; Beckenstein, Tanya; Yaron, Shlomit et al. (2022): Effectiveness of a second BNT162b2 booster vaccine against hospitalization and death from COVID-19 in adults aged over 60 years. In: Nature medicine 28 (7), S. 1486–1490. DOI: 10.1038/s41591-022-01832-0.
9. Bar-On, Yinon M.; Goldberg, Yair; Mandel, Micha; Bodenheimer, Omri; Amir, Ofra; Freedman, Laurence et al. (2022): Protection by 4th dose of BNT162b2 against Omicron in Israel. DOI: 10.1101/2022.02.01.22270232.
10. Baum, Ulrike; Poukka, Eero; Leino, Tuija; Kilpi, Terhi; Nohynek, Hanna; Palmu, Arto A. (2022): High vaccine effectiveness against severe Covid-19 in the elderly in Finland before and after the emergence of Omicron. DOI: 10.1101/2022.03.11.22272140.
11. Breznik, Jessica A.; Rahim, Ahmad; Kajaks, Tara; Hagerman, Megan; Bilaver, Lucas; Colwill, Karen et al. (2022): Protection from Omicron infection in residents of nursing and retirement homes in Ontario, Canada. DOI: 10.1101/2022.06.28.22277016.
12. Britton, Amadea; Embi, Peter J.; Levy, Matthew E.; Gaglani, Manjusha; DeSilva, Malini B.; Dixon, Brian E. et al. (2022): Effectiveness of COVID-19 mRNA Vaccines Against COVID-19-Associated Hospitalizations Among Immunocompromised Adults During SARS-CoV-2 Omicron Predominance - VISION Network, 10 States, December 2021-August 2022. In: MMWR Morb. Mortal. Wkly. Rep. 71 (42), S. 1335–1342. DOI: 10.15585/mmwr.mm7142a4.
13. Buchan, Sarah A.; Chung, Hannah; Brown, Kevin A.; Austin, Peter C.; Fell, Deshayne B.; Gubbay, Jonathan B. et al. (2022): Estimated Effectiveness of COVID-19 Vaccines Against Omicron or Delta Symptomatic Infection and Severe Outcomes. In: JAMA network open 5 (9), e2232760. DOI: 10.1001/jamanetworkopen.2022.32760.
14. Buchan, Sarah A.; Nguyen, Lena; Wilson, Sarah E.; Kitchen, Sophie A.; Kwong, Jeffrey C. (2022): Vaccine effectiveness of BNT162b2 against Omicron and Delta outcomes in adolescents. DOI: 10.1101/2022.04.07.22273319.
15. Butt, Adeel A.; Talisa, Victor B.; Shaikh, Obaid S.; Omer, Saad B.; Mayr, Florian B. (2022): Relative Vaccine Effectiveness of a SARS-CoV-2 mRNA Vaccine Booster Dose Against the Omicron Variant. In: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. DOI: 10.1093/cid/ciac328.
16. Carazo, Sara; Skowronski, Danuta M.; Brisson, Marc; Sauvageau, Chantal; Brousseau, Nicholas; Gilca, Rodica et al. (2022): Protection against Omicron re-infection conferred by prior heterologous SARS-CoV-2 infection, with and without mRNA vaccination. DOI: 10.1101/2022.04.29.22274455.
17. Castelli, Juan Manuel; Rearte, Analia; Olszevicki, Santiago; Voto, Carla; Del Valle Juarez, María; Pesce, Martina et al. (2022): Effectiveness of mRNA-1273, BNT162b2, and BBIBP-CorV vaccines against infection and mortality in children in Argentina, during predominance of delta and omicron covid-19 variants: test negative, case-control study. In: BMJ (Clinical research ed.) 379, e073070. DOI: 10.1136/bmj-2022-073070.
18. Castillo Suarez, Milena; Khaoua, Hamid; Courtejoie, Noémie (2022): Vaccine-induced and naturally-acquired protection against Omicron and Delta symptomatic infection and severe COVID-19 outcomes, France, December 2021 to January 2022. In: Euro surveillance : bulletin European sur les maladies transmissibles = European communicable disease bulletin 27 (16). DOI: 10.2807/1560-7917.ES.2022.27.16.2200250.
19. Cerqueira-Silva, Thiago; Shah, Syed Ahmar; Robertson, Chris; Sanchez, Mauro Niskier; Katikireddi, Srinivasa Vittal; Araújo Oliveira, Vinicius de et al. (2022): Waning of mRNA Boosters after Homologous Primary Series with BNT162b2 or ChAdOx1 Against Symptomatic Infection and Severe COVID-19 in Brazil and Scotland: A Test-Negative Design Case-Control Study. In: SSRN Journal. DOI: 10.2139/ssrn.4082927.

20. Chatzilena, Anastasia; Hyams, Catherine; Challen, Robert; Marlow, Robin; King, Jade; Adegbite, David et al. (2022): Effectiveness of BNT162b2 COVID-19 Vaccination in Prevention of Hospitalisations and Severe Disease in Adults with Delta (B.1.617.2) and Omicron (B.1.1.529) Variant SARS-CoV-2 Infection: A Prospective Test Negative Case-Control Study. In: SSRN Journal. DOI: 10.2139/ssrn.4216690.
21. Chemaitelly, Hiam; AlMukdad, Sawsan; Ayoub, Houssein H.; Altarawneh, Heba N.; Coyle, Peter; Tang, Patrick et al. (2022): Effectiveness of the BNT162b2 vaccine against SARS-CoV-2 infection among children and adolescents in Qatar. DOI: 10.1101/2022.07.26.22278045.
22. Chemaitelly, Hiam; Ayoub, Houssein H.; AlMukdad, Sawsan; Coyle, Peter; Tang, Patrick; Yassine, Hadi M. et al. (2022): Duration of mRNA vaccine protection against SARS-CoV-2 Omicron BA.1 and BA.2 subvariants in Qatar. In: Nature communications 13 (1), S. 3082. DOI: 10.1038/s41467-022-30895-3.
23. Chemaitelly, Hiam; Ayoub, Houssein H.; Tang, Patrick; Coyle, Peter; Yassine, Hadi M.; Al Thani, Asmaa A. et al. (2022): COVID-19 primary series and booster vaccination and immune imprinting. DOI: 10.1101/2022.10.31.22281756.
24. Chemaitelly, Hiam; Ayoub, Houssein H.; Tang, Patrick; Coyle, Peter; Yassine, Hadi M.; Al Thani, Asmaa A. et al. (2022): Long-term COVID-19 booster effectiveness by infection history and clinical vulnerability and immune imprinting. DOI: 10.1101/2022.11.14.22282103.
25. Chemaitelly, Hiam; Nagelkerke, Nico; Ayoub, Houssein H.; Coyle, Peter; Tang, Patrick; Yassine, Hadi M. et al. (2022): Duration of immune protection of SARS-CoV-2 natural infection against reinfection in Qatar. DOI: 10.1101/2022.07.06.22277306.
26. Chiew, Calvin J.; Premikha, M.; Chong, Chia Yin; Wei, Wycliffe E.; Ong, Benjamin; Lye, David Chien et al. (2022): Effectiveness of primary series and booster vaccination against SARS-CoV-2 infection and hospitalisation among adolescents aged 12–17 years in Singapore: a national cohort study. In: The Lancet Infectious Diseases. DOI: 10.1016/S1473-3099(22)00573-4.
27. Coccio, Silvia; Zabeo, Federico; Tremolada, Giulia; Facchin, Giacomo; Venturato, Giovanni; Marcon, Thomas et al. (2022): COVID-19 Vaccine Effectiveness against Omicron Variant among Underage Subjects: The Veneto Region's Experience. In: Vaccines 10 (8). DOI: 10.3390/vaccines10081362.
28. Cohen-Stavi, Chandra J.; Magen, Ori; Barda, Noam; Yaron, Shlomit; Peretz, Alon; Netzer, Doron et al. (2022): BNT162b2 Vaccine Effectiveness against Omicron in Children 5 to 11 Years of Age. In: N Engl J Med 387 (3), S. 227–236. DOI: 10.1056/NEJMoa2205011.
29. Fabiani, Massimo; Mateo-Urdiales, Alberto; Sacco, Chiara; Rota, Maria Cristina; Petrone, Daniele; Bressi, Marco et al. (2022): Relative effectiveness of a 2nd booster dose of COVID-19 mRNA vaccine up to four months post administration in individuals aged 80 years or more in Italy: A retrospective matched cohort study. In: Vaccine. DOI: 10.1016/j.vaccine.2022.11.013.
30. Ferdinands, Jill M.; Rao, Suchitra; Dixon, Brian E.; Mitchell, Patrick K.; DeSilva, Malini B.; Irving, Stephanie A. et al. (2022): Waning of vaccine effectiveness against moderate and severe covid-19 among adults in the US from the VISION network: test negative, case-control study. In: BMJ 379, e072141. DOI: 10.1136/bmj-2022-072141.
31. Florentino, Pilar T. V.; Millington, Tristan; Cerqueira-Silva, Thiago; Robertson, Chris; Araújo Oliveira, Vinicius de; Júnior, Juracy B. S. et al. (2022): Vaccine effectiveness of two-dose BNT162b2 against symptomatic and severe COVID-19 among adolescents in Brazil and Scotland over time: a test-negative case-control study. In: The Lancet Infectious Diseases. DOI: 10.1016/S1473-3099(22)00451-0.
32. Fowlkes, Ashley L.; Yoon, Sarang K.; Lutrick, Karen; Gwynn, Lisa; Burns, Joy; Grant, Lauren et al. (2022): Effectiveness of 2-Dose BNT162b2 (Pfizer BioNTech) mRNA Vaccine in Preventing SARS-CoV-2 Infection Among Children Aged 5-11 Years and Adolescents Aged 12-15 Years - PROTECT Cohort, July 2021-February 2022. In: MMWR Morb. Mortal. Wkly. Rep. 71 (11), S. 422–428. DOI: 10.15585/mmwr.mm7111e1.
33. Gazit, Sivan; Saciuk, Yaki; Perez, Galit; Peretz, Asaf; Pitzer, Virginia E.; Patalon, Tal (2022): Short term, relative effectiveness of four doses versus three doses of BNT162b2 vaccine in people aged 60 years and older in Israel: retrospective, test negative, case-control study. In: BMJ 377, e071113. DOI: 10.1136/bmj-2022-071113.
34. González, Soledad; Olszevicki, Santiago; Gaiano, Alejandra; Baino, Ana Nina Varela; Regairaz, Lorena; Salazar, Martín et al. (2022): Effectiveness of BBIBP-CorV, BNT162b2 and mRNA-1273 vaccines against hospitalisations among children and adolescents during the Omicron outbreak in Argentina: A retrospective cohort study. In: Lancet Regional Health. Americas 13, S. 100316. DOI: 10.1016/j.lana.2022.100316.
35. González, Soledad; Olszevicki, Santiago; Gaiano, Alejandra; Salazar, Martín; Regairaz, Lorena; Varela Baino, Ana Nina et al. (2022): Protection of homologous and heterologous boosters after primary schemes of rAd26-rAd5, ChAdOx1 nCoV-19 and BBIBP-CorV during the Omicron outbreak in adults of 50 years and older in Argentina: a test-negative case-control study. DOI: 10.1101/2022.09.25.22280341.
36. Gram, Mie Agermose; Emborg, Hanne-Dorthe; Schelde, Astrid Blicher; Friis, Nikolaj Ulrik; Nielsen, Katrine Finderup; Moustsen-Helms, Ida Rask et al. (2022): Vaccine effectiveness against SARS-CoV-2 infection or COVID-19 hospitalization with the Alpha, Delta, or Omicron SARS-CoV-2 variant: A nationwide Danish cohort study. In: PLoS medicine 19 (9), e1003992. DOI: 10.1371/journal.pmed.1003992.
37. Grewal, Ramandip; Kitchen, Sophie A.; Nguyen, Lena; Buchan, Sarah A.; Wilson, Sarah E.; Costa, Andrew P.; Kwong, Jeffrey C. (2022): Effectiveness of a fourth dose of covid-19 mRNA vaccine against the omicron variant among long term care residents in Ontario, Canada: test negative design study. In: BMJ 378, e071502. DOI: 10.1136/bmj-2022-071502.
38. Grewal, Ramandip; Nguyen, Lena; Buchan, Sarah A.; Wilson, Sarah E.; Costa, Andrew P.; Kwong, Jeffrey C. (2022): Effectiveness and Duration of Protection of a Fourth Dose of COVID-19 mRNA Vaccine among Long-Term Care Residents in Ontario, Canada. DOI: 10.1101/2022.09.29.22280526.
39. Grewal, Ramandip; Nguyen, Lena; Buchan, Sarah A.; Wilson, Sarah E.; Nasreen, Sharifa; Austin, Peter C. et al. (2022): Effectiveness of mRNA COVID-19 vaccine booster doses against Omicron severe outcomes. DOI: 10.1101/2022.10.31.22281766.
40. Hansen, Christian Holm; Friis, Nikolaj Ulrik; Bager, Peter; Stegger, Marc; Fonager, Jannik; Fomsgaard, Anders et al. (2022): Risk of Reinfection, Vaccine Protection, and Severity of Infection with the BA.5 Omicron Subvariant: A Danish Nation-Wide Population-Based Study. In: SSRN Journal. DOI: 10.2139/ssrn.4165630.
41. Hansen, Christian; Schelde, Astrid; Moustsen-Helm, Ida; Embor, Hanne-Dorthe; Eriksen, Rasmus; Stegger, Marc et al. (2022): Vaccine effectiveness against infection and COVID-19-associated hospitalisation with the Omicron (B.1.1.529) variant after vaccination with the BNT162b2 or mRNA-1273 vaccine: A nationwide Danish cohort study. DOI: 10.21203/rs.3.rs-1486018/v1.

42. Ioannou, George N.; Bohnert, Amy S. B.; O'Hare, Ann M.; Boyko, Edward J.; Maciejewski, Matthew L.; Smith, Valerie A. et al. (2022): Effectiveness of mRNA COVID-19 vaccine boosters against infection, hospitalization and death: a target trial emulation in the omicron (B.1.1.529) variant era. DOI: 10.1101/2022.06.15.22276466.
43. Ionescu, Iulia G.; Skowronski, Danuta M.; Sauvageau, Chantal; Chuang, Erica; Ouakki, Manale; Kim, Shinhye; Serres, Gaston de (2022): BNT162b2 effectiveness against Delta & Omicron variants in teens by dosing interval and duration. DOI: 10.1101/2022.06.27.22276790.
44. Jara, Alejandro; Cuadrado, Cristobal; Undurraga, Eduardo A.; García, Christian; Nájera, Manuel; Bertoglia, María Paz et al. (2022): Effectiveness and duration of a second COVID-19 vaccine booster. DOI: 10.1101/2022.10.03.22280660.
45. Kim, Sara S.; Chung, Jessie R.; Talbot, H. Keipp; Grijalva, Carlos G.; Wernli, Karen J.; Kiniry, Erika et al. (2022): Effectiveness of 2 and 3 mRNA COVID-19 Vaccines Doses against Omicron and Delta-Related Outpatient Illness among Adults, October 2021 – February 2022 7. DOI: 10.1101/2022.04.06.22273535.
46. Kirsebom, Freja; Andrews, Nick; Sachdeva, Ruchira; Stowe, Julia; Ramsay, Mary; Bernal, Jamie Lopez (2022): Effectiveness of ChAdOx1-S COVID-19 Booster Vaccination against the Omicron and Delta variants in England. DOI: 10.1101/2022.04.29.22274483.
47. Kislaya, Irina; Machado, Ausenda; Magalhães, Sarah; Rodrigues, Ana Paula; Franco, Rafael; Leite, Pedro Pinto et al. (2022): COVID-19 mRNA vaccine effectiveness (second and first booster dose) against hospitalisation and death during Omicron BA.5 circulation: cohort study based on electronic health records, Portugal, May to July 2022. In: Euro surveillance : bulletin European sur les maladies transmissibles = European communicable disease bulletin 27 (37). DOI: 10.2807/1560-7917.ES.2022.27.37.2200697.
48. Klein, Nicola P.; Stockwell, Melissa S.; Demarco, Maria; Gaglani, Manjusha; Kharbanda, Anupam B.; Irving, Stephanie A. et al. (2022): Effectiveness of COVID-19 Pfizer-BioNTech BNT162b2 mRNA Vaccination in Preventing COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Nonimmunocompromised Children and Adolescents Aged 5–17 Years - VISION Network, 10 States, April 2021–January 2022. In: MMWR Morb. Mortal. Wkly. Rep. 71 (9), S. 352–358. DOI: 10.15585/mmwr.mm7109e3.
49. Lauring, Adam S.; Tenforde, Mark W.; Chappell, James D.; Gaglani, Manjusha; Ginde, Adit A.; McNeal, Tresa et al. (2022): Clinical severity of, and effectiveness of mRNA vaccines against, covid-19 from omicron, delta, and alpha SARS-CoV-2 variants in the United States: prospective observational study. In: BMJ 376, e069761. DOI: 10.1136/bmj-2021-069761.
50. Lin, Dan-Yu; Gu, Yu; Xu, Yangjianchen; Wheeler, Bradford; Young, Hayley; Sunny, Shadia Khan et al. (2022): Association of Primary and Booster Vaccination and Prior Infection With SARS-CoV-2 Infection and Severe COVID-19 Outcomes. In: JAMA 328 (14), S. 1415–1426. DOI: 10.1001/jama.2022.17876.
51. Lind, Margaret L.; Robertson, Alexander James; Silva, Julio; Warner, Frederick; Coppi, Andreas C.; Price, Nathan et al. (2022): Effectiveness of Primary and Booster COVID-19 mRNA Vaccination against Omicron Variant SARS-CoV-2 Infection in People with a Prior SARS-CoV-2 Infection 397. DOI: 10.1101/2022.04.19.22274056.
52. Link-Gelles, Ruth; Ciesla, Allison Avrich; Fleming-Dutra, Katherine E.; Smith, Zachary R.; Britton, Amadea; Wiegand, Ryan E. et al. (2022): Effectiveness of Bivalent mRNA Vaccines in Preventing Symptomatic SARS-CoV-2 Infection - Increasing Community Access to Testing Program, United States, September–November 2022. In: MMWR Morb. Mortal. Wkly. Rep. 71 (48), S. 1526–1530. DOI: 10.15585/mmwr.mm7148e1.
53. Link-Gelles, Ruth; Levy, Matthew E.; Gaglani, Manjusha; Irving, Stephanie A.; Stockwell, Melissa; Dascomb, Kristin et al. (2022): Effectiveness of 2, 3, and 4 COVID-19 mRNA Vaccine Doses Among Immunocompetent Adults During Periods when SARS-CoV-2 Omicron BA.1 and BA.2/BA.2.12.1 Sublineages Predominated - VISION Network, 10 States, December 2021–June 2022. In: MMWR. Morbidity and mortality weekly report 71 (29), S. 931–939. DOI: 10.15585/mmwr.mm7129e1.
54. Link-Gelles, Ruth; Levy, Matthew E.; Natarajan, Karthik; Reese, Sarah E.; Naleway, Allison L.; Grannis, Shaun J. et al. (2022): Association between COVID-19 mRNA vaccination and COVID-19 illness and severity during Omicron BA.4 and BA.5 sublineage periods. DOI: 10.1101/2022.10.04.22280459.
55. Liu, Bette; Gidding, Heather; Stepien, Sandrine; Cretikos, Michelle; Macartney, Kristine (2022): Relative Effectiveness of COVID-19 Vaccination with 3 Compared to 2 Doses Against SARS-CoV-2 B.1.1.529 (Omicron) Among an Australian Population with Low Prior Rates of SARS-CoV-2 Infection. In: SSRN Journal. DOI: 10.2139/ssrn.4142075.
56. Magen, Ori; Waxman, Jacob G.; Makov-Assif, Maya; Vered, Roni; Dicker, Dror; Hernán, Miguel A. et al. (2022): Fourth Dose of BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting. In: N Engl J Med 386 (17), S. 1603–1614. DOI: 10.1056/NEJMoa2201688.
57. McConeghy, Kevin W.; White, Elizabeth M.; Blackman, Carolyn; Santostefano, Christopher M.; Lee, Yoojin; Rudolph, James L. et al. (2022): Effectiveness of a Second COVID-19 Vaccine Booster Dose Against Infection, Hospitalization, or Death Among Nursing Home Residents - 19 States, March 29–July 25, 2022. In: MMWR Morb. Mortal. Wkly. Rep. 71 (39), S. 1235–1238. DOI: 10.15585/mmwr.mm7139a2.
58. Mimura, Wataru; Ishiguro, Chieko; Maeda, Megumi; Murata, Fumiko; Fukuda, Haruhisa (2022): Effectiveness of messenger RNA vaccines against infection with SARS-CoV-2 during the periods of Delta and Omicron variant predominance in Japan: the Vaccine Effectiveness, Networking, and Universal Safety (VENUS) study. In: International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases 125, S. 58–60. DOI: 10.1016/j.ijid.2022.10.001.
59. Monge, Susana; Rojas-Benedicto, Ayelén; Olmedo, Carmen; Mazagatos, Clara; José Sierra, María; Limia, Aurora et al. (2022): Effectiveness of mRNA vaccine boosters against infection with the SARS-CoV-2 omicron (B.1.1.529) variant in Spain: a nationwide cohort study. In: The Lancet Infectious Diseases 22 (9), S. 1313–1320. DOI: 10.1016/S1473-3099(22)00292-4.
60. Montez-Rath, Maria E.; Garcia, Pablo; Han, Jialin; Cadden, LinaCel; Hunsader, Patti; Morgan, Curt et al. (2022): SARS-CoV-2 infection during the Omicron surge among patients receiving dialysis: the role of circulating receptor-binding domain antibodies and vaccine doses. In: medRxiv. DOI: 10.1101/2022.03.15.22272426.
61. Muhsen, Khitam; Maimon, Nimrod; Mizrahi, Amiel Yaron; Boltansky, Boris; Bodenheimer, Omri; Diamant, Zafirra Hillel et al. (2022): Association of Receipt of the Fourth BNT162b2 Dose With Omicron Infection and COVID-19 Hospitalizations Among Residents of Long-term Care Facilities. In: INTEMED 182 (8), S. 859–867. DOI: 10.1001/jamainternmed.2022.2658.
62. Ng, Oon Tek; Marimuthu, Kalisvar; Lim, Nigel; Lim, Ze Qin; Thevasagayam, Natascha May; Koh, Vanessa et al. (2022): Analysis of COVID-19 Incidence and Severity Among Adults Vaccinated With 2-Dose mRNA COVID-19 or Inactivated SARS-CoV-2 Vaccines With and Without Boosters in Singapore. In: JAMA network open 5 (8), e2228900. DOI: 10.1001/jamanetworkopen.2022.28900.

63. Norddahl, Gudmundur L.; Melsted, Pall; Gunnarsdottir, Kristbjorg; Halldorsson, Gisli H.; Olafsdottir, Thorunn A.; Gylfason, Arnaldur et al. (2022): Effect of booster vaccination against Delta and Omicron variants in Iceland. DOI: 10.1101/2022.02.26.22271509.
64. Nordström, Peter; Ballin, Marcel; Nordström, Anna (2022): Safety and effectiveness of COVID-19 mRNA vaccination and risk factors for hospitalisation caused by the omicron variant in 0.8 million adolescents: A nationwide cohort study in Sweden. DOI: 10.1101/2022.10.19.22281286.
65. Patalon, Tal; Saciuk, Yaki; Peretz, Asaf; Perez, Galit; Lurie, Yoav; Maor, Yasmin; Gazit, Sivan (2022): Waning effectiveness of the third dose of the BNT162b2 mRNA COVID-19 vaccine. In: *Nature communications* 13 (1), S. 3203. DOI: 10.1038/s41467-022-30884-6.
66. Petrie, Joshua G.; King, Jennifer P.; McClure, David L.; Rolfs, Melissa A.; Meece, Jennifer K.; Belongia, Edward A.; McLean, Huong Q. (2022): Effectiveness of COVID-19 mRNA vaccine booster dose relative to primary series during a period of Omicron circulation. DOI: 10.1101/2022.04.15.22273915.
67. Piché-Renaud, Pierre-Philippe; Swayze, Sarah; Buchan, Sarah; Wilson, Sarah; Austin, Peter C.; Morris, Shaun K. et al. (2022): Vaccine Effectiveness of BNT162b2 Against Omicron in Children Aged 5-11 Years: A Test-Negative Design. In: *SSRN Journal*. DOI: 10.2139/ssrn.4176388.
68. Plumb, Ian D.; Feldstein, Leora R.; Barkley, Eric; Posner, Alexander B.; Bregman, Howard S.; Hagen, Melissa Briggs; Gerhart, Jacqueline L. (2022): Effectiveness of COVID-19 mRNA Vaccination in Preventing COVID-19-Associated Hospitalization Among Adults with Previous SARS-CoV-2 Infection - United States, June 2021–February 2022. In: *MMWR. Morbidity and mortality weekly report* 71 (15), S. 549–555. DOI: 10.15585/mmwr.mm7115e2.
69. Powell, Annabel A.; Kirsebom, Freja; Stowe, Julia; Ramsay, Mary E.; Lopez-Bernal, Jamie; Andrews, Nick; Ladhani, Shamez N. (2022): Protection against symptomatic disease with the delta and omicron BA.1/BA.2 variants of SARS-CoV-2 after infection and vaccination in adolescents: national observational test-negative case control study, August 2021 to March 2022, England. DOI: 10.1101/2022.08.19.22278987.
70. Price, Ashley M.; Olson, Samantha M.; Newhams, Margaret M.; Halasa, Natasha B.; Boom, Julie A.; Sahni, Leila C. et al. (2022): BNT162b2 Protection against the Omicron Variant in Children and Adolescents. In: *N Engl J Med* 386 (20), S. 1899–1909. DOI: 10.1056/NEJMoa2202826.
71. Rennert, Lior; Ma, Zichen; McMahan, Christopher S.; Dean, Delphine (2022): Covid-19 vaccine effectiveness against general SARS-CoV-2 infection from the omicron variant: A retrospective cohort study. DOI: 10.1101/2022.05.06.22274771.
72. Risk, Malcolm; Hayek, Salim S.; Schiopu, Elena; Yuan, Liyang; Shen, Chen; Shi, Xu et al. (2022): COVID-19 vaccine effectiveness against omicron (B.1.1.529) variant infection and hospitalisation in patients taking immunosuppressive medications: a retrospective cohort study. In: *The Lancet Rheumatology* 383, S. 2603. DOI: 10.1016/S2665-9913(22)00216-8.
73. Rudan, Igor; Millington, Tristan; Antal, Karen; Grange, Zoe; Fenton, Lynda; Sullivan, Christopher et al. (2022): BNT162b2 COVID-19 vaccination uptake, safety, effectiveness and waning in children and young people aged 12–17 years in Scotland. In: *The Lancet regional health. Europe* 23, S. 100513. DOI: 10.1016/j.lanepe.2022.100513.
74. Sharma, Aditya; Oda, Gina; Holodniy, Mark (2022): Effectiveness of mRNA-based vaccines during the emergence of SARS-CoV-2 Omicron variant. In: *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America*. DOI: 10.1093/cid/ciac325.
75. Šmíd, Martin; Berec, Luděk; Májek, Ondřej; Pavlík, Tomáš; Jarkovský, Jiří; Weiner, Jakub et al. (2022): Protection by vaccines and previous infection against the Omicron variant of SARS-CoV-2. DOI: 10.1101/2022.02.24.22271396.
76. Stowe, Julia; Andrews, Nick; Kirsebom, Freja; Ramsay, Mary; Bernal, Jamie Lopez (2022): Effectiveness of COVID-19 vaccines against Omicron and Delta hospitalisation: test negative case-control study 386. DOI: 10.1101/2022.04.01.22273281.
77. Surie, Diya; Bonnell, Levi; Adams, Katherine; Gaglani, Manjusha; Ginde, Adit A.; Douin, David J. et al. (2022): Effectiveness of Monovalent mRNA Vaccines Against COVID-19-Associated Hospitalization Among Immunocompetent Adults During BA.1/BA.2 and BA.4/BA.5 Predominant Periods of SARS-CoV-2 Omicron Variant in the United States - IVY Network, 18 States, December 26, 2021–August 31, 2022. In: *MMWR Morb. Mortal. Wkly. Rep.* 71 (42), S. 1327–1334. DOI: 10.15585/mmwr.mm7142a3.
78. Tan, Celine Y.; Chiew, Calvin J.; Lee, Vernon J.; Ong, Benjamin; Lye, David Chien; Tan, Kelvin Bryan (2022): Effectiveness of a Fourth Dose of COVID-19 mRNA Vaccine Against Omicron Variant Among Elderly People in Singapore. In: *Annals of internal medicine*. DOI: 10.7326/M22-2042.
79. Tartof, Sara Y.; Frankland, Timothy B.; Slezak, Jeff M.; Puzniak, Laura; Hong, Vennis; Xie, Fagen et al. (2022): Effectiveness Associated With BNT162b2 Vaccine Against Emergency Department and Urgent Care Encounters for Delta and Omicron SARS-CoV-2 Infection Among Adolescents Aged 12 to 17 Years. In: *JAMA network open* 5 (8), e2225162. DOI: 10.1001/jamanetworkopen.2022.25162.
80. Tartof, Sara Y.; Slezak, Jeff M.; Puzniak, Laura; Hong, Vennis; Xie, Fagen; Ackerson, Bradley K. et al. (2022): BNT162b2 Effectiveness and Durability Against BA.1 and BA.2 Hospital and Emergency Department Admissions in a Large US Health System: A Test-Negative Design. In: *SSRN Journal*. DOI: 10.2139/ssrn.4150500.
81. Tartof, Sara Y.; Slezak, Jeff M.; Puzniak, Laura; Hong, Vennis; Xie, Fagen; Ackerson, Bradley K. et al. (2022): Durability of BNT162b2 vaccine against hospital and emergency department admissions due to the omicron and delta variants in a large health system in the USA: a test-negative case-control study. In: *The Lancet Respiratory Medicine* 10 (7), S. 689–699. DOI: 10.1016/S2213-2600(22)00101-1.
82. Tsang, Nicole Ngai Yung; So, Hau Chi; Cowling, Benjamin J.; Leung, Gabriel; Ip, Dennis Kai Ming (2022): Effectiveness of BNT162b2 and CoronaVac COVID-19 Vaccination Against Asymptomatic and Symptomatic Infection of SARS-CoV-2 Omicron BA.2 in Hong Kong. In: *SSRN Journal*. DOI: 10.2139/ssrn.4200539.
83. Tseng, Hung Fu; Ackerson, Bradley K.; Bruxvoort, Katia J.; Sy, Lina S.; Tubert, Julia E.; Lee, Gina S. et al. (2022): Effectiveness of mRNA-1273 against infection and COVID-19 hospitalization with SARS-CoV-2 Omicron subvariants: BA.1, BA.2, BA.2.12.1, BA.4, and BA.5. DOI: 10.1101/2022.09.30.22280573.
84. Tseng, Hung Fu; Ackerson, Bradley K.; Luo, Yi; Sy, Lina S.; Talarico, Carla A.; Tian, Yun et al. (2022): Effectiveness of mRNA-1273 against SARS-CoV-2 Omicron and Delta variants. In: *Nature medicine* 28 (5), S. 1063–1071. DOI: 10.1038/s41591-022-01753-y.
85. Veneti, Lamprini; Berild, Jacob Dag; Watle, Sara Viksmoen; Starrfelt, Jostein; Greve-Isdahl, Margrethe; Langlete, Petter et al. (2022): Vaccine effectiveness with BNT162b2 (Comirnaty, Pfizer-BioNTech) vaccine against reported SARS-CoV-2 Delta and Omicron infection among adolescents, Norway, August 2021 to January 2022. DOI: 10.1101/2022.03.24.22272854.

86. Wan, Eric Yuk Fai; Mok, Anna Hoi Ying; Yan, Vincent Ka Chun; Ying Chan, Cheyenne I.; Wang, Boyuan; Lai, Francisco Tsz Tsun et al. (2022): Effectiveness of BNT162b2 and CoronaVac vaccinations against SARS-CoV-2 omicron infection in people aged 60 years or above: a case-control study. In: Journal of travel medicine. DOI: 10.1093/jtm/taac119.
87. Wang, Xiaofeng; Zein, Joe; Ji, Xinge; Lin, Dan-Yu (2022): Impact of Vaccination, Prior Infection, and Therapy on Delta and Omicron Variants 62. DOI: 10.1101/2022.03.24.22272901.
88. Yan, Vincent Ka Chun; Wan, Eric Yuk Fai; Ye, Xuxiao; Mok, Anna Hoi Ying; Lai, Francisco Tsz Tsun; Chui, Celine Sze Ling et al. (2022): Effectiveness of BNT162b2 and CoronaVac vaccinations against mortality and severe complications after SARS-CoV-2 Omicron BA.2 infection: a case-control study. In: Emerging microbes & infections, S. 1–48. DOI: 10.1080/22221751.2022.2114854.
89. Young-Xu, Yinong; Zwain, Gabrielle M.; Izurieta, Hector S.; Korves, Caroline; Powell, Ethan I.; Smith, Jeremy et al. (2022): Effectiveness of mRNA COVID-19 vaccines against Omicron and Delta variants in a matched test-negative case-control study among US veterans. In: BMJ Open 12 (8). DOI: 10.1136/bmjopen-2022-063935.
90. Zambrano, Laura D.; Newhams, Margaret M.; Olson, Samantha M.; Halasa, Natasha B.; Price, Ashley M.; Orzel, Amber O. et al. (2022): BNT162b2 mRNA Vaccination Against COVID-19 is Associated with Decreased Likelihood of Multisystem Inflammatory Syndrome in U.S. Children Ages 5-18 Years. In: Clinical infectious diseases: an official publication of the Infectious Diseases Society of America. DOI: 10.1093/cid/ciac637.

Supplement 2 Table S8: Excluded primary studies with reason for exclusion (n=48)

No.	Author (date)	Reason for exclusion	Category
1	Altarawneh (06.01.2022)	Date (inclusion from 12.02.2022, RKI Review)	Date
2	Buchan (28.01.2022)	Date (inclusion from 12.02.2022, RKI Review)	Date
3	Canetti (09.11.2022)	Editorial	Article Format
4	Carazo (27.06.2022)	HCW	Study population
5	Carlsen (01.06.2022)	Newborns/Infants	Study population
6	Cerdeira-Silva (01.07.2022)	Correspondence	Article Format
7	Cerdeira-Silva (18.07.2022)	Vaccine CoronaVac	Vaccine type
8	Cheng (11.08.2022)	Letter	Article format
9	Chin (27.05.2022)	Prison Inmates	Study population
10	Cohen (02.08.2022)	HCW	Study population
11	Collie (14.09.2022)	Editorial	Article format
12	Collie (29.12.2021)	Date (inclusion from 12.02.2022, RKI Review)	Date
13	Consonni (19.10.2022)	HCW	Study population
14	Ferdinands (11.02.2022)	Date (inclusion from 12.02.2022, RKI Review)	Date
15	Florentino (13.08.2022)	Vaccine CoronaVac	Vaccine type
16	Glatman-Freedman (31.03.2022)	not Omicron-specific	Study population
17	Gray (09.06.2022)	HCW	Study population
18	Guedalia (11.07.2022)	Pregnant women	Study population
19	Halasa (22.06.2022)	Infants	Study population
20	Hansen (23.12.2021)	Date (inclusion from 02/12/2022, RKI review)	Date
21	Hertz (15.08.2022)	HCW	Study population
22	Huang (09.09.2022)	Vaccine Ad5-nCoV, BBIBP-CorV, CoronaVac	Vaccine type
23	Jara (23.05.2022)	CoronaVac vaccine	Vaccine type
24	Jorgensen (08.11.2022)	Newborns/infants	Study population
25	Kim (29.08.2022)	HCW	Study population
26	Moghnieh (22.09.2022)	Airline employees	Study population
27	Natarajan (29.03.2022)	Report	Article format
28	Penayo (06/2022)	No access to full text	Article format
29	Powell (21.03.2022)	Comment	Article format
30	Ranzani (16.08.2022)	Vaccine CoronaVac	Vaccine type
31	Regev-Yochay (15.02.2022)	HCW	Study population
32	Richterman (06.06.2022)	HCW	Study population
33	Risk (08.10.2022)	No access to full text	Article format

34	Schrag (26.09.2022)	Pregnant	Study population
35	Simwanza (08.06.2022)	Prison inmates	Study population
36	Spensley (26.01.2022)	Date (inclusion from 12.02.2022, RKI Review).	Date
37	Stirrup (09.08.2022)	HCW	Study population
38	Suah (02.05.2022)	Letter	Article Format
39	Tan (13.09.2022)	Letter	Article format
40	Tartof (25.10.2022)	Correspondence	Article format
41	Tenforde (25.03.2022)	Report	Article format
42	Thompson (21.01.2022)	Date (Inclusion from 12.02.2022, RKI Review)	Date
43	UKHSA (03.11.2022)	Report	Article format
44	UKHSA (14.01.2022)	Report	Article format
45	Wan (17.08.2022)	Letter	Article format
46	Willet (26.01.2022)	Date (inclusion from 12.02.2022, RKI Review)	Date
47	Yoon (06.04.2022)	HCW	Study population
48	Zerbo (18.10.2022)	Newborns/infants	Study population

- Altarawneh, Heba; Chemaitlely, Hiam; Tang, Patrick; Hasan, Mohammad R.; Qassim, Suelen; Ayoub, Houssein H. et al. (2022): Protection afforded by prior infection against SARS-CoV-2 reinfection with the Omicron variant. DOI: 10.1101/2022.01.05.22268782.
- Buchan, Sarah A.; Chung, Hannah; Brown, Kevin A.; Austin, Peter C.; Fell, Deshayne B.; Gubbay, Jonathan B. et al. (2022): Effectiveness of COVID-19 vaccines against Omicron or Delta symptomatic infection and severe outcomes. DOI: 10.1101/2021.12.30.21268565.
- Canetti, Michal; Barda, Noam; Gilboa, Mayan; Indenbaum, Victoria; Asraf, Keren; Gonen, Tal et al. (2022): Six-Month Follow-up after a Fourth BNT162b2 Vaccine Dose. In: *N Engl J Med* 387 (22), S. 2092–2094. DOI: 10.1056/NEJMc2211283.
- Carazo, Sara; Skowronski, Danuta M.; Brisson, Marc; Barkati, Sapha; Sauvageau, Chantal; Brousseau, Nicholas et al. (2022): Protection against Omicron BA.2 reinfection conferred by primary Omicron or pre-Omicron infection with and without mRNA vaccination. DOI: 10.1101/2022.06.23.22276824.
- Carlsen, Ellen Øen; Magnus, Maria C.; Oakley, Laura; Fell, Deshayne B.; Greve-Isdahl, Margrethe; Kinge, Jonas Minet; Häberg, Siri E. (2022): Association of COVID-19 Vaccination During Pregnancy With Incidence of SARS-CoV-2 Infection in Infants. In: *INTEMED* 182 (8), S. 825–831. DOI: 10.1001/jamainternmed.2022.2442.
- Cerqueira-Silva, Thiago; Araujo Oliveira, Vinicius de; Paixão, Enny S.; Florentino, Pilar Tavares Veras; Penna, Gerson O.; Pearce, Neil et al. (2022): Vaccination plus previous infection: protection during the omicron wave in Brazil. In: *The Lancet Infectious Diseases* 22 (7), S. 945–946. DOI: 10.1016/S1473-3099(22)00288-2.
- Cerqueira-Silva, Thiago; Araujo Oliveira, Vinicius de; Paixão, Enny S.; Júnior, Juracy Bertoldo; Penna, Gerson O.; Werneck, Guilherme L. et al. (2022): Duration of protection of CoronaVac plus heterologous BNT162b2 booster in the Omicron period in Brazil. In: *Nature communications* 13 (1), S. 4154. DOI: 10.1038/s41467-022-31839-7.
- Cheng, Franco Wing Tak; Fan, Min; Wong, Carlos King Ho; Chui, Celine Sze Ling; Lai, Francisco Tsz Tsun; Li, Xue et al. (2022): The effectiveness and safety of mRNA (BNT162b2) and inactivated (CoronaVac) COVID-19 vaccines among individuals with chronic kidney diseases. In: *Kidney international* 102 (4), S. 922–925. DOI: 10.1016/j.kint.2022.07.018.
- Chin, Elizabeth T.; Leidner, David; Lamson, Lauren; Lucas, Kimberley; Studdert, David M.; Goldhaber-Fiebert, Jeremy D. et al. (2022): Protection against Omicron conferred by mRNA primary vaccine series, boosters, and prior infection. In: *medRxiv*. DOI: 10.1101/2022.05.26.22275639.
- Cohen, Matan J.; Oster, Yonatan; Moses, Alon E.; Spitzer, Avishay; Benenson, Shmuel (2022): Association of Receiving a Fourth Dose of the BNT162b Vaccine With SARS-CoV-2 Infection Among Health Care Workers in Israel. In: *JAMA network open* 5 (8), e2224657. DOI: 10.1001/jamanetworkopen.2022.24657.
- Collie, Shirley; Champion, Jared; Moultrie, Harry; Bekker, Linda-Gail; Gray, Glenda (2022): Effectiveness of BNT162b2 Vaccine against Omicron Variant in South Africa. In: *N Engl J Med* 386 (5), S. 494–496. DOI: 10.1056/NEJMc2119270.
- Collie, Shirley; Nayager, Jiren; Bamford, Lesley; Bekker, Linda-Gail; Zylstra, Matt; Gray, Glenda (2022): Effectiveness and Durability of the BNT162b2 Vaccine against Omicron Sublineages in South Africa. In: *N Engl J Med*. DOI: 10.1056/NEJMc2210093.
- Consonni, Dario; Lombardi, Andrea; Mangioni, Davide; Bono, Patrizia; Oggioni, Massimo; Uceda Renteria, Sara et al. (2022): Immunogenicità ed efficacia del vaccino anti-COVID-19 BNT162b2 in una coorte di operatori sanitari a Milano. In: *Epidemiologia e prevenzione* 46 (4), S. 250–258. DOI: 10.19191/EP22.4.A513.065.
- Ferdinands, Jill M.; Rao, Suchitra; Dixon, Brian E.; Mitchell, Patrick K.; DeSilva, Malini B.; Irving, Stephanie A. et al. (2022): Waning 2-Dose and 3-Dose Effectiveness of mRNA Vaccines Against COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance - VISION Network, 10 States, August 2021-January 2022. In: *MMWR Morb. Mortal. Wkly. Rep.* 71 (7), S. 255–263. DOI: 10.15585/mmwr.mm7107e2.
- Florentino, Pilar T. V.; Alves, Flávia J. O.; Cerqueira-Silva, Thiago; Oliveira, Vinicius de Araújo; Júnior, Juracy B. S.; Jantsch, Adelson G. et al. (2022): Vaccine effectiveness of CoronaVac against COVID-19 among children in Brazil during the Omicron period. In: *Nature communications* 13 (1), S. 4756. DOI: 10.1038/s41467-022-32524-5.

16. Glatman-Freedman, Aharona; Bromberg, Michal; Hershkovitz, Yael; Sefty, Hanna; Kaufman, Zalman; Dichtiar, Rita; Keinan-Boker, Lital (2022): Effectiveness of BNT162b2 Vaccine Booster against SARS-CoV-2 Infection and Breakthrough Complications, Israel. In: Emerging infectious diseases 28 (5), S. 948–956. DOI: 10.3201/eid2805.220141.
17. Gray, Glenda; Collie, Shirley; Goga, Ameena; Garrett, Nigel; Champion, Jared; Seocharan, Ishen et al. (2022): Effectiveness of Ad26.COV2.S and BNT162b2 Vaccines against Omicron Variant in South Africa. In: N Engl J Med 386 (23), S. 2243–2245. DOI: 10.1056/NEJMc2202061.
18. Guedalia, Joshua; Lipschuetz, Michal; Calderon-Margalit, Ronit; Cohen, Sarah M.; Goldman-Wohl, Debra; Kaminer, Tali et al. (2022): Effectiveness of BNT162b2 mRNA COVID-19 Third Vaccines During Pregnancy: A National Observational Study in Israel. In: SSRN Journal. DOI: 10.2139/ssrn.4159559.
19. Halasa, Natasha B.; Olson, Samantha M.; Staat, Mary A.; Newhams, Margaret M.; Price, Ashley M.; Pannaraj, Pia S. et al. (2022): Maternal Vaccination and Risk of Hospitalization for Covid-19 among Infants. In: N Engl J Med 387 (2), S. 109–119. DOI: 10.1056/NEJMoa2204399.
20. Hansen, Christian Holm; Schelde, Astrid Blicher; Moustsen-Helm, Ida Rask; Emborg, Hanne-Dorthe; Krause, Tyra Grove; Mølbak, Kåre; Valentiner-Branth, Palle (2021): Vaccine effectiveness against SARS-CoV-2 infection with the Omicron or Delta variants following a two-dose or booster BNT162b2 or mRNA-1273 vaccination series: A Danish cohort study.
21. Hertz, Tomer; Levy, Shlomia; Ostrovsky, Daniel; Oppenheimer, Hannah; Zismanov, Shosh; Kuzmina, Alona et al. (2022): Correlates of protection for booster doses of the BNT162b2 vaccine. DOI: 10.21203/rs.3.rs-1915346/v1.
22. Huang, Zhuoying; Xu, Shuangfei; Liu, Jiechen; Wu, Linlin; Qiu, Jing; Wang, Nan et al. (2022): Effectiveness of inactivated and Ad5-nCoV COVID-19 vaccines against SARS-CoV-2 Omicron BA. 2 variant infection, severe illness, and death. DOI: 10.1101/2022.09.04.22279587.
23. Jara, Alejandro; Undurraga, Eduardo A.; Zubizarreta, José R.; González, Cecilia; Acevedo, Johanna; Pizarro, Alejandra et al. (2022): Effectiveness of CoronaVac in children 3–5 years of age during the SARS-CoV-2 Omicron outbreak in Chile. In: Nature medicine 28 (7), S. 1377–1380. DOI: 10.1038/s41591-022-01874-4.
24. Jorgensen, Sarah C. J.; Hernandez, Alejandro; Fell, Deshayne; Austin, Peter C.; D'Souza, Rohan; Guttmann, Astrid et al. (2022): Effectiveness of Maternal mRNA COVID-19 Vaccination During Pregnancy Against Delta and Omicron SARS-CoV-2 Infection and Hospitalization in Infants: A Test-Negative Design Study. In: SSRN Journal. DOI: 10.2139/ssrn.4246651.
25. Kim, Sung Ran; Kang, Hyeyon Jeong; Jeong, Hye Rin; Jang, Su Yeon; Lee, Jae Eun; Da Kim, Eun et al. (2022): Relative Effectiveness of COVID-19 Vaccination in Healthcare Workers: 3-Dose Versus 2-Dose Vaccination. In: Journal of Korean medical science 37 (35), e267. DOI: 10.3346/jkms.2022.37.e267.
26. Moghnieh, Rima; El Hajj, Claude; Abdallah, Dania; Jbeily, Nayla; Bizri, Abdul Rahman; Sayegh, Mohamed H. (2022): Immunogenicity and Effectiveness of Primary and Booster Vaccine Combination Strategies during Periods of SARS-CoV-2 Delta and Omicron Variants. In: Vaccines 10 (10). DOI: 10.3390/vaccines10101596.
27. Natarajan, Karthik; Prasad, Namrata; Dascomb, Kristin; Irving, Stephanie A.; Yang, Duck-Hye; Gaglani, Manjusha et al. (2022): Effectiveness of Homologous and Heterologous COVID-19 Booster Doses Following 1 Ad.26.COV2.S (Janssen Johnson & Johnson) Vaccine Dose Against COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults - VISION Network, 10 States, December 2021–March 2022. In: MMWR Morb. Mortal. Wkly. Rep. 71 (13), S. 495–502. DOI: 10.15585/mmwr.mm7113e2.
28. Kein Zugriff
29. Powell, Annabel A.; Kirsebom, Freja; Stowe, Julia; McOwat, Kelsey; Saliba, Vanessa; Ramsay, Mary E. et al. (2022): Effectiveness of BNT162b2 against COVID-19 in adolescents. In: The Lancet Infectious Diseases 22 (5), S. 581–583. DOI: 10.1016/S1473-3099(22)00177-3.
30. Ranzani, Otavio T.; Hitchings, Matt D.T.; Leite de Melo, Rosana; França, Giovanny V. A. de; Fernandes, Cássia de Fátima R.; Lind, Margaret L. et al. (2022): Effectiveness of an Inactivated Covid-19 Vaccine with Homologous and Heterologous Boosters against Omicron in Brazil. DOI: 10.1101/2022.03.30.22273193.
31. Regev-Yochay, Gili; Gonen, Tal; Gilboa, Mayan; Mandelboim, Michal; Indenbaum, Victoria; Amit, Sharon et al. (2022): 4th Dose COVID mRNA Vaccines' Immunogenicity & Efficacy Against Omicron VOC. DOI: 10.1101/2022.02.15.22270948.
32. Richterman, Aaron; Behrman, Amy; Brennan, Patrick J.; O'Donnell, Judith A.; Snider, Christopher K.; Chaiyachati, Krisda H. (2022): Durability of SARS-CoV-2 mRNA Booster Vaccine Protection Against Omicron Among Health Care Workers with a Vaccine Mandate. In: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. DOI: 10.1093/cid/ciac454.
33. Risk, Malcolm; Miao, Heidi; Freed, Gary; Shen, Chen (2022): Vaccine Effectiveness, School Reopening, and Risk of Omicron Infection Among Adolescents Aged 12–17 Years. In: The Journal of adolescent health : official publication of the Society for Adolescent Medicine. DOI: 10.1016/j.jadohealth.2022.09.006.
34. Schrag, Stephanie J.; Verani, Jennifer R.; Dixon, Brian E.; Page, Jessica M.; Butterfield, Kristen A.; Gaglani, Manjusha et al. (2022): Estimation of COVID-19 mRNA Vaccine Effectiveness Against Medically Attended COVID-19 in Pregnancy During Periods of Delta and Omicron Variant Predominance in the United States. In: JAMA network open 5 (9), e2233273. DOI: 10.1001/jamanetworkopen.2022.33273.
35. Simwanza, John; Hines, Jonas Z.; Sinyange, Danny; Sinyange, Nyambe; Mulenga, Chilufya; Hanyinza, Sarah et al. (2022): COVID-19 vaccine effectiveness during a prison outbreak when the Omicron was the dominant circulating variant—Zambia, December 2021. DOI: 10.1101/2022.05.06.22274701.
36. Spensley, Katrina J.; Gleeson, Sarah; Martin, Paul; Thomson, Tina; Clarke, Candice L.; Pickard, Graham et al. (2022): Comparison of Vaccine Effectiveness Against the Omicron (B.1.1.529) Variant in Hemodialysis Patients. In: Kidney international reports 7 (6), S. 1406–1409. DOI: 10.1016/j.kir.2022.04.005.
37. Stirrup, Oliver; Shrotri, Madhumita; Adams, Natalie L.; Krutikov, Maria; Nacer-Laidi, Hadjer; Azmi, Borscha et al. (2022): Clinical effectiveness of SARS-CoV-2 booster vaccine against Omicron infection in residents and staff of Long-Term Care Facilities: a prospective cohort study (VIVALDI). DOI: 10.1101/2022.08.08.22278532.
38. Suah, Jing Lian; Tng, Boon Hwa; Tok, Peter Seah Keng; Husin, Masliyana; Thevananthan, Thevesh; Peariasamy, Kalaiarasu M.; Sivasampu, Sheamini (2022): Real-world effectiveness of homologous and heterologous BNT162b2, CoronaVac, and AZD1222 booster vaccination against Delta and Omicron SARS-CoV-2 infection. In: Emerging microbes & infections 11 (1), S. 1343–1345. DOI: 10.1080/22221751.2022.2072773.

39. Tan, Celine Y.; Chiew, Calvin J.; Lee, Vernon J.; Ong, Benjamin; Lye, David Chien; Tan, Kelvin Bryan (2022): Effectiveness of a Fourth Dose of COVID-19 mRNA Vaccine Against Omicron Variant Among Elderly People in Singapore. In: *Annals of internal medicine*. DOI: 10.7326/M22-2042.
40. Tartof, Sara Y.; Slezak, Jeff M.; Puzniak, Laura; Hong, Vennis; Frankland, Timothy B.; Ackerson, Bradley K. et al. (2022): BNT162b2 vaccine effectiveness against SARS-CoV-2 omicron BA.4 and BA.5. In: *The Lancet. Infectious diseases* 22 (12), S. 1663–1665. DOI: 10.1016/S1473-3099(22)00692-2.
41. Tenforde, Mark W.; Self, Wesley H.; Gaglani, Manjusha; Ginde, Adit A.; Douin, David J.; Talbot, H. Keipp et al. (2022): Effectiveness of mRNA Vaccination in Preventing COVID-19-Associated Invasive Mechanical Ventilation and Death - United States, March 2021-January 2022. In: *MMWR Morb. Mortal. Wkly. Rep.* 71 (12), S. 459–465. DOI: 10.15585/mmwr.mm7112e1.
42. Thompson, Mark G.; Natarajan, Karthik; Irving, Stephanie A.; Rowley, Elizabeth A.; Griggs, Eric P.; Gaglani, Manjusha et al. (2022): Effectiveness of a Third Dose of mRNA Vaccines Against COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance - VISION Network, 10 States, August 2021-January 2022. In: *MMWR Morb. Mortal. Wkly. Rep.* 71 (4), S. 139–145. DOI: 10.15585/mmwr.mm7104e3.
43. UKHSA (2022): COVID-19 vaccine surveillance report. Week 44. Online verfügbar unter https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1115385/Vaccine_surveillance_report__week-44.pdf.
44. UKHSA (2022): COVID-19 vaccine surveillance report. Week 4. Online verfügbar unter https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1050721/Vaccine-surveillance-report-week-4.pdf.
45. Wan, Eric Yuk Fai; Mok, Anna Hoi Ying; Yan, Vincent Ka Chun; Wang, Boyuan; Zhang, Ran; Hong, Sabrina Nan et al. (2022): Vaccine effectiveness of BNT162b2 and CoronaVac against SARS-CoV-2 Omicron BA.2 infection, hospitalisation, severe complications, cardiovascular disease and mortality in patients with diabetes mellitus: A case control study. In: *The Journal of infection* 85 (5), e140-e144. DOI: 10.1016/j.jinf.2022.08.008.
46. Willett, Brian J.; Grove, Joe; MacLean, Oscar A.; Wilkie, Craig; Logan, Nicola; Lorenzo, Giuditta de et al. (2022): The hyper-transmissible SARS-CoV-2 Omicron variant exhibits significant antigenic change, vaccine escape and a switch in cell entry mechanism. DOI: 10.1101/2022.01.03.21268111.
47. Yoon, Sarang K.; Hegmann, Kurt T.; Thiese, Matthew S.; Burgess, Jefferey L.; Ellingson, Katherine; Lutrick, Karen et al. (2022): Protection with a Third Dose of mRNA Vaccine against SARS-CoV-2 Variants in Frontline Workers. In: *N Engl J Med* 386 (19), S. 1855–1857. DOI: 10.1056/NEJMc2201821.
48. Zerbo, Ousseny; Ray, G. Thomas; Fireman, Bruce; Layefsky, Evan; Goddard, Kristin; Lewis, Edwin et al. (2022): Maternal SARS-CoV-2 Vaccination and Infant Protection Against SARS-CoV-2 During the First 6 Months of Life. In: Research square. DOI: 10.21203/rs.3.rs-2143552/v1.